

CURRICULUM VITAE

JEAN-FRANCOIS DUFOUR, M.D.

- Address:** University Clinic of Visceral Surgery and Medicine
Inselspital
BHH, D-115
Freiburgstrasse
CH-3010 Bern
+41-31-632 21 11 (Tel) / +41-31-632 74 89 (Fax)
jean-francois.dufour@dkf.unibe.ch
www.swissliver.ch www.linkedin.com
- Birth:** Geneva, Switzerland, 1960
- Citizenship:** Swiss
- Education:**
- High School:** Classical Studies, Geneva, Switzerland. 1976 - 1979
- Medical Study:** Geneva Medical School. 1979 - 1986
- Mathematical studies:** University of Geneva. 1979 - 1984
- Mathematics degree:** University of Geneva. 1984
- Medical degree:** Geneva Medical School. 1986
- Doctorate in medicine:** Geneva Medical School. 1990
Thesis "les méningites de l'adulte à Genève. Revue de 257 cas"
- Certification:**
- Swiss Board of Internal Medicine** ('Spécialiste FMH en médecine interne'): 1993
- Swiss Board of Gastroenterology and Hepatology** ('Spécialiste FMH en gastroenterology et hépatologie'): 2003
- Other Examinations:**
- FMGEMS: 1986
- Diploma of Biostatistics, University Marie Curie, Paris: 1989
- FLEX: 1993
- License:**
- Swiss Confederation: 1986

Residency and fellowship:

Department of Internal Medicine, University Hospital Geneva (Switzerland). Prof. Waldvogel
October 1986 - September 1989

Department of Clinical Pharmacology, University Hospital Berne (Switzerland). Prof. Reichen
October 1989 – September 1991

Research Training:

Department of Physiology, Tufts University, Boston. Prof. Arias
October 1991 - June 1995

Clinical Training in Gastroenterology

Fellow, New England Medical Center, Tufts University Medical School, Boston. Prof. Kaplan
July 1995 - June 1997

Academic Appointments

July 1997 - March 2000

Oberarzt

Department of Clinical Pharmacology
University of Berne, Switzerland

March 2000 – March 2004

Venia Docendi for Internal Medicine, especially Gastroenterology and Hepatology
University of Berne, Switzerland

March 2004 – January 2011

Titular Professor

February 2007 – January 2011

Leitender Arzt

Department of Clinical Pharmacology
University of Berne, Switzerland

February 2011 – present

Chefarzt and Klinikdirektor

Professor of Hepatology

Universitätsklinik für Viszerale Chirurgie und Medizin

Inselspital

Bern, Switzerland

Scientific Prizes, Funding and Awards:

Swiss National Science Foundation, fellowship (1991)

Schweizerische Stiftung für medizinische und biologische Stipendien (1992)

Janggen Pöhn Stiftung (1993)

American Liver Foundation Fellowship Award (1993)

American Gastroenterology Association, Advanced Research Training Award (1994)

Swiss National Science Foundation (1997)

Best Poster at the Annual Meeting of the Swiss Society for Gastroenterology and
Hepatology (1998)

Honorary prize of the Swiss Association for Gastroenterology and Hepatology (2000)
Novartis Stiftung (2000)
Swiss National Science Foundation (2001): 'Regulation of the IP3 receptor isoforms'
Büttner Stiftung (2001)
Swiss Cancer League (2002)
Swiss Transplant Research Award (2002)
Schering-Plough Award, Annual Meeting of the European Association for the Study of the Liver (2002)
Swiss National Science Foundation (2003): 'Hint2, a new Hint protein'.
Swiss National Science Foundation (2004): 'Systemic gene therapy of hepatocellular carcinoma by tumor restricted, self-limited E2F-1 overexpression from the hTERT promoter' (Co-investigator).
Oncosuisse (2003).
Swiss National Science Foundation (2004): 'Ion-selective microelectrode array for the detection of intracellular calcium activities' (Co-investigator).
Hepatology prize of the Swiss Association for Gastroenterology and Hepatology (2003)
Stanley Thomas Johnson Stiftung (2004)
Hepatology prize of the Swiss Association for Gastroenterology and Hepatology (2005)
Swiss National Science Foundation (2006): 'Hint2, a mitochondrial tumor suppressor'
Swiss National Science Foundation (2006): 'Swiss Hepatitis C Cohort Study' (Co-investigator).
Sassela Foundation (2007)
Novartis Stiftung (2007)
Désirée and Nils Yde Stiftung (2007)
Oncosuisse (2007)
Swiss National Science Foundation - Indo Swiss Joint Research Programme (2009): 'Studying the effect of mTOR inhibitor and sunitinib on hepatic stellate cells' (Co-Principal Investigator).
Swiss National Science Foundation (2009): 'Hint1, Hint2, apoptosis and cell proliferation'.
Swiss National Science Foundation (2009): 'The link between aberrant MET signaling and DNA repair pathways in liver tumor cells as a target for sensitization to DNA damaging agents' (Co-investigator).
FP7-HEALTH-2009-single-stage, Proposal No: 241762. Fatty liver: Inhibition of progression (FLIP).
Oncosuisse (2010)
Mach-Gaensslen Stiftung (2010)
Sander Stiftung (2011)
Gerber Stiftung (2011)
Swiss National Foundation (2012-2015): 'Hint proteins a closer look'.
Swiss National Foundation (2013-2015): 'Metabolic pathways governing liver carcinogenesis and regeneration'. Sinergia grant
Swiss National Foundation (2015-2017). 'Nitric oxide in hepatocellular carcinoma: mechanistic and therapeutic implications'. IndoSwiss grant
Swiss Cancer Research (2015-2018): 'How physical activity influences carcinogenesis: the case of HCC'
Swiss National Foundation (2015-2018). 'Hint2 and nutritional stress'.
Swiss National Foundation (2016-2018): 'Metabolic control of hepatocytes proliferation in regeneration and cancer'. Sinergia grant
EU Litmus (2017): 'Liver Investigation: Testing Marker Utility in Steatohepatitis'.

Invited lectures:

1. 'AIDS und die Leber'. Tag der Leber. Bern, Januar 1998.
2. 'Hépatite autoimmune'. Colloque de Gastroentérologie, Lausanne, March 1998.
3. 'La stéatohépatite non-alcoolique'. Colloque de Gastroentérologie. Genève, April 1998.
4. 'Expression of IP₃ receptor isoforms during liver cirrhosis'. INSERM U442. Orsay, May 1999.
5. 'Erhöhte Leberwerte'. In collaboration with Dr. P. Bertschinger. Tag der Leber. Zürich, September 1999.
6. 'Indikationen und Resultate der Lebertransplantation'. Europaeum Medicum Collegium. Frutigen, September 1999.
7. 'Is hepatic cirrhosis reversible?' Symposium honoring Prof. Kaplan. New England Medical Center. Boston, March 2000.
8. 'Regulation of the hepatic IP₃ receptor/Ca²⁺ channel'. Liver Research Center, Albert Einstein College of Medicine. New York, March 2000.
9. 'Non-alcoholic Steatohepatitis'. State of the art lecture. Annual Meeting Swiss Society for Gastroenterology and Hepatology. Lucerne, October 2000.
10. 'Tocopherol and antioxidants in the treatment of the non-alcoholic steatohepatitis'. Falk Symposium 121. The Hague, October 2000.
11. 'Viral etiology of hepatic cancers'. Swiss Society of Oncology. Lausanne, November 2000.
12. 'La stéatohépatite non-alcoolique, un maladie plus importante que l'hépatite C'. Journée d'Hépatologie. Lausanne, December 2000.
13. 'Hepatocellular Calcium homeostasis – Role in bile formation and cholestasis'. Zürcher Hepatologie Seminare. Zürich, May 2001.
14. 'Survival pathways and preconditioning in liver transplantation'. The Transplantation Society, 7th Basic Sciences Symposium. Thun, August 2001.
15. 'Critères de mise en liste pour le patient éthylique'. Symposium Addictions et transplantation hépatique. Lausanne, September 2001.
16. 'Hepatologische Abklärung des Rundherdes bei Leberzirrhose'. Interdisziplinäre Viszeralchirurgie Symposium Inselspital. Bern, October 2001.
17. 'Alcohol and liver transplantation'. Annual Meeting of the Swiss Society for Gastroenterology and Hepatology. Interlaken, October 2001.
18. 'Non-alcoholic Steatohepatitis: When and how to treat?' Zürcher Hepatologie Postgraduate Kurs. Zürich, March 2002.
19. 'Tests hépatiques anormaux, quand est-ce trop de gras?' Journée Romande d'Hépatologie. Sierre, March 2002.
20. 'Est-ce que la fibrose peut régresser?' Journée Romande d'Hépatologie. Sierre, March 2002.
21. 'Leberbeteiligung bei IBD'. 3. Berner IBD Symposium. Berne, March 2002.
22. 'NASH: Diagnose und Konsequenz'. 10. Fortbildungskurs der FAGAS. Brunnen, May 2002.
23. 'Leberbiopsie bei chronischer Hepatitis C- ja oder nein?' Hepatitis C Update Symposium. Yverdon, June 2002.
24. 'Non-Alcoholic Fatty Liver Disease: as harmless as we think?' Zürcher Leber-Tage Symposium. Zürich, September 2002.
25. 'Nicht-alkoholische Fettlebererkrankung: Ein Update'. Churer Medizin Symposium. Chur, September 2002.
26. 'La stéatose qui tue'. Journée d'Hépatologie. Neuchâtel, December 2002.
27. 'Nicht-alkoholische Fettlebererkrankung'. Update Symposium nach UEGW. Zürich, Januar 2003.
28. 'Nicht-alkoholische Fettlebererkrankung'. Weiterbildung Inselspital. Curriculum Internal medicine. Bern, September 2003.

29. 'Expression and regulation of gap junctions in rat cholangiocytes'. Annual Meeting of the Swiss Society for Gastroenterology and Hepatology. Basel, September 2003.
30. 'Tests hépatiques perturbés chez la personne âgé'. Deuxième Journée d'Automne d'actualité en Gastroentérologie et Hépatologie. Lausanne, September 2003.
31. 'Aetiologie und Pathogenese der NASH'. Fortbildung Hirslanden Klinik. Zürich, Oktober 2003.
32. 'IP₃ receptors isoforms in liver pathobiology'. Workshop on Calcium dynamics. Mathematical Biosciences Institute. Columbus, Ohio, January 2004.
33. 'Nicht-alkoholische Steatohepatitis'. Update Gastroenterologie. Weiterbildung Kantonsspital Aarau, February 2004.
34. 'IP₃ receptors isoforms in liver pathophysiology'. Sixth Calreticulin workshop. Zermatt, April 2004.
35. 'NASH: Update 2004'. 11. Fortbildungskurs der FAGAS. Brunnen, April 2004.
36. 'Rapamycin for hepatocellular carcinoma'. Second Suren Seghal Rapamycin Symposium. Washington, May 2004.
37. 'Atteinte hépatique iatrogène'. Workshop. Assemblée annuelle de la société suisse de médecine interne. Lausanne, May 2004.
38. 'Malignant disease after liver transplantation'. Transplantation and cancer. Zürich, June 2004.
39. 'Elévation des transaminases. Que faire quand on a tout cherché?'. Annual Meeting of the Swiss Society for Gastroenterology and Hepatology. Montreux, September 2004.
40. 'NASH'. 14th World Congress of the International Association of Surgeons, Gastroenterologists. Zürich, September 2004.
41. 'Hepatitis: State of the Art für den Grundversorger'. 27. Kongress der Schweizerischen Gesellschaft für Allgemeinmedizin. Bern. Oktober 2004.
42. 'Erhöhte Transaminasen, was nun?'. Hausärztesfortbildung. Niederbipp. November 2004.
43. 'Angiogenesis and hepatocellular carcinoma'. Liver grand round. Newcastle-upon-Tyne. November 2004.
44. 'Benign recurrent intrahepatic cholestasis'. Gastro-Kolloquium. Bern. May 2005.
45. 'NASH: Lifestyle modifications and other treatments'. Tag der Leber 2005. Bern. June 2005.
46. 'Aktuelles zu Diagnose und Therapie der Hepatitis B und C'. Fortbildung Hirserbad. June 2005.
47. 'Diagnose Cholangiocarcinoma bei primär biliärer Sklerose'. Interdisziplinäre Viszeralchirurgie. Bern. September 2005.
48. 'Test hépatiques perturbés: que faire?'. Formation continue de l'hôpital du Jura bernois. Sonceboz. Octobre 2005.
49. 'Leber und Rheumatologie'. Weiterbildung für Rheumatologe. Egerkingen. April 2006.
50. 'AST et ALT: précis et juste, importance clinique'. Assemblée annuelle de la Société Suisse de Médecine Interne. Lausanne. Mai 2006.
51. 'Löcher in der Leber'. Gastrokolloquium. Bern. August 2006.
52. 'Nebenwirkungsmanagement Interferon – gestützter Therapien'. Fortbildung Inselspital. Bern Oktober 2006.
53. 'Hepatocellular carcinoma, where do we stand'. Liver rounds, Sydney Australia October 2006.
54. 'Hepatitis C Prävention, Diagnose und Behandlung'. Fortbildung 'ABC der Hepatitis'. Bern Oktober 2006.
55. 'Prise en charge du patient sous interféron'. Formation continue de l'hôpital du Jura bernois. Sonceboz. Janvier 2007.
56. 'Angiogenesis in the development and therapy of hepatocellular carcinoma'. 10. Interdisziplinäres Gastroenterologisch-Hepatologisches Wintertreffen. Obergurgl, Tirol. March 2007.

57. 'Tumor Suppressors'. Symposium EASL Annual Meeting. Barcelona. April 2007.
58. 'Leber und Rheuma'. 3. Berner Fortbildungskurs Rheumatologie und klinische Immunologie. Bern. April 2007.
59. 'Medikamentöse Therapien von Lebererkrankungen: was gibt es Neues?'. Diagnostisch-Therapeutisches Seminar. Inselspital, Bern. April 2007.
60. 'What is new in basic research in the field of liver disease?' Société Suisse de chirurgie. Lausanne Juin. 2007.
61. 'Hépatite virales 2007'. Formation postgraduée. Delémont. Juin 2007.
62. 'Tests hépatiques anormaux lors d'un bilan de routine'. Journée du foie. Genève. Juin 007.
63. 'Hepatocellular carcinoma, Update 2007'. Curriculum Innere Medizin. Inselspital. Bern Juni 2007.
64. 'Virale Hepatitiden in Pädiatrie'. Fortbildung Inselspital. Bern. August 2007.
65. 'Aszites 2007'. Gastrokolloquium, Inselspital. Bern. August 2007.
66. 'Steatohepatitis'. Weiterbildungsprogramm. Waidspital, Zürich. September 2007.
67. 'Charakteristika des Cholangiocarcinoms'. Jahreskongress SGG. Lausanne. September 2007.
68. 'Aszites 2007'. 2. Symposium. Swiss HPB-Center. Zürich. Oktober 2007.
69. 'HCC – What about medical treatment?' 4. Zürich Postgraduate Course in Hepatology. Wolfsberg. November 2007.
70. 'Targeting hypercholesterolemia'. EASL Monothematic Conference. Newcastle. December 2007.
71. 'Hint1, Hint2 et carcinoma hépatocellulaire'. Séminaire INSERM U889 et IFR66, Université Victor Segalen Bordeaux 2, Bordeaux. December 2007.
72. 'Ascites : les erreurs les plus fréquentes dans la prise en charge'. Cours de formation postgraduée et continue en médecine interne. Neuchâtel. Janvier 2008.
73. 'Hepatocellular carcinoma and mTOR inhibitors'. Annual meeting of the Swiss Transplantation Society. Interlaken. January 2008.
74. 'Nexavar et Chimio-embolisation'. Symposium de la Clinique de Genolier. Genève, février 2008.
75. 'Treatment of hepatocellular carcinoma: combination local-systemic'. EASL single topic conference on hepatocellular carcinoma. Prag. June 2008.
76. 'Fettleber, ein Problem der Zukunft'. SASL Tag der Leber. Zürich. June 2008.
77. 'Traitement hépato-protecteur et NASH'. NASH Symposium. Paris. June 2008.
78. 'Angiogenèse du carcinome hépatocellulaire'. 63mes Journées de l'Association Française de l'Etude du Foie. Paris. September 2008.
79. 'New pharmacological approaches of hepatocellular carcinoma'. UEGW. Vienna. October 2008.
80. 'Angiogenesis and liver cancer'. UEGW. Vienna. October 2008.
81. 'Hint1, Hint2 and hepatocellular carcinoma'. Séminaire CIMA, University of Navarra, Pamplona. November 2008.
82. 'Hepatocarcinogenesis in chronic viral hepatitis'. Jahrestagung Schweizerische Gesellschaft für Pathologie. Liestal. November 2008.
83. 'HCC: neue therapeutische Ansätze'. Gastrokolloquium. Inselspital. November 2008.
84. 'NASH: wie weiter?' Langenthal. November 2008.
85. 'Comment améliorer le pronostic du CHC'. Journées médico-chirurgicales d'hépatologie et de gastroentérologie. Genève. Novembre 2008.
86. 'Schwierig zu behandelnde Patienten: Nonresponder/relapser'. 3. Praxis Workshop für Aerzte. Baden. December 2008.
87. 'Perturbations des enzymes hépatiques, quand faut-il arrêter les investigations?' Demi-journée de formation continue. Neuchâtel. Décembre 2008.

88. 'Treatment of HCC: inhibition of angiogenesis and beyond'. European Perspective lecture. Frankfurt. March 2009.
89. Integrating systemic and locoregional treatment'. 2nd Hepatocellular Carcinoma UK Group Meeting. London. March 2009.
90. 'Experimental Models of HCC-important tools for research'. State-of-the-Art. 12. Interdisziplinäres Gastroenterologisch-Hepatologisches Wintertreffen. Serfaus. April 2009.
91. 'Sorafenib, which indications?' International hepatobiliary, pancreatic and transplantation days. Geneva. May 2009.
92. 'Angiogenic pathways in the pathogenesis of HCC'. Liver cirrhosis as a vascular disease. Wien. May 2009.
93. 'Hepatozelluläres Karzinom wie weiter?' Weiterbildung. Aachen. June 2009.
94. 'NASH:Soll, muss oder kann man behandeln?' Interdisziplinäre Viszerale Chirurgie und Medizin. Inselspital. September 2009.
95. 'Experimental Data with Pipeline Drugs'. ILCA, Annual Meeting. Milan. September 2009.
96. 'mTOR as a novel target in hepatocellular carcinoma'. ILCA, Annual Meeting. Milan. September 2009.
97. 'Anti-oxidants and cyto-protective agents'. EASL special conference on NALFD/NASH and related metabolic diseases. Bologna. September 2009.
98. 'Global Update in Hepatocellular carcinoma: EASL Perspective'. AASLD, Annual Meeting. Boston. November 2009.
99. 'Strategies for targeted therapies in hepatocellular carcinoma'. PATH Meeting. Milan. November 2009.
100. 'Hepatocellular carcinoma and liver transplantation'. 7th Symposium – Medical Aspects of Organ Transplantation. Bern. November 2009.
101. 'Fatty liver disease: Risk assessment of a silent killer'. 5th Zürich Postgraduate Course in Hepatology. Wolfsberg. December 2009.
102. 'Hint1, Hint2 and liver pathophysiology'. Indian Institute for Technology. Chennai. March 2010.
103. 'Hepatocellular carcinoma'. AU-KBC Center, Anna University. Chennai. March 2010.
104. 'Update Cholestasis'. 14. Fortbildungskurs der SGG. Brunnen. April 2010.
105. 'Nonalcoholic fatty liver disease'. Weiterbildung. Zieglerspital. April 2010.
106. 'Combining local and systemic therapies, what for?' Symposium EASL Annual Meeting. Vienna. April 2010.
107. 'Treatment of HCC in era of targeted therapy'. The 7th National Conference of Liver Disease. Xiamen, China. June 2010.
108. 'Update Hepatitis'. Fortbildung. Kantonspital Olten. September 2010.
109. 'Preclinical Rationale for targeting mTOR in HCC'. Novartis Symposium. The 4th ILCA Annual Conference. Montreal. September 2010.
110. 'Molecular Pathways in HCC'. Australian Gastroenterology Week 2010. Gold Coast Convention Center, Australia. October 2010.
111. 'HCC- Systemic therapies'. Australian Gastroenterology Week 2010. Gold Coast Convention Center, Australia. October 2010.
112. 'Vitamin E and UDCA in the management of NAFLD'. Australian Gastroenterology Week 2010. Gold Coast Convention Center, Australia. October 2010.
113. 'NAFLD – NASH – Cirrhosis'. Annual Meeting of the Swiss Society of Endocrinology. Bern. November 2010.
114. 'Hepatozelluläres Karzinom – Das Update für die Praxis'. 4. Praxis Workshop "für Aerzte. Baden. November 2010.

115. 'HCC – Nicht chirurgische Therapieoptionen'. Interdisziplinäres Gastroforum. Basel. Dezember 2010.
116. 'Rationale for New Targeted Therapies for HCC'. Symposium 'Improving Outcomes with Systemic Treatments for HCC'. 21st APASL Annual Meeting. Bangkok February 2011.
117. 'Molecular Targeted Therapy for Current and Future Approach'. APASL-EASL joint Symposium on HCC. 21st APASL Annual Meeting. Bangkok February 2011.
118. 'Candide ou l'optimisme: conte philosophique à propos de l'hépatocarcinome'. Paris Créteil. Mai 2011.
119. 'Das Hepatozelluläre Karzinom: Gründe für das Screening'. Interdisziplinäre Viszeral Chirurgie und Medizin. Bern. Juni 2011.
120. 'Advanced HCC: improving patient outcomes through targeted treatments'. ESMO 13th World Congress on Gastrointestinal Cancer. Barcelona. June 2011.
121. 'Hepatocellular carcinoma: current management'. Keynote lecture. SGGSSG Annual Meeting. Lausanne. September 2011.
122. 'Rational for targeted and combination pharmacological therapy in HCC: preclinical and clinical data'. PATH Meeting. Bologna. October 2011.
123. 'Indications for transplantation and management of patients with HCC while on the waiting list'. Belgian week of Gastroenterology. Ostend. February 2012.
124. 'Angiogenesis in hepatocellular carcinoma: effects of targeted therapy'. International Conference on Angiogenesis. Chennai. March 2012.
125. 'Metabolomic in HCC'. Joined Symposium ILCA-EASL. International liver Congress. Barcelona. April 2012.
126. 'Fettleber beim metabolischen Syndrom – harmlos oder gefährlich?'. SASL Tag der Leber. St-Gallen. August 2012.
127. 'Linking signalling pathways and novel therapies'. Workshop. ILCA. Berlin. September 2012.
128. 'Everolimus in the treatment of advanced HCC'. Symposium. ILCA. Berlin. September 2012.
129. 'Neue Medikamente in der Behandlung der Hepatitis C'. Kolloquium im Spital Netz Bern. Tiefenau. September 2012.
130. 'Risque carcinologique de la NASH'. Société royale belge de gastroentérologie. Brussels. October 2012.
131. 'Management of hepatocellular carcinoma'. National Cancer Research Institute. Liverpool. November 2012.
132. 'EASL perspective on the place of NASH among chronic liver diseases in Western countries'. EASL-INASL conference on NASH. Kolkata. December 2012.
133. 'Metabolomics and evolving modalities'. Kolkata. EASL-INASL conference on NASH. Kolkata. December 2012.
134. 'Immunsuppression nach Lebertransplantation'. Symposium Swiss Society of Pharmacology and Toxicology. Bern. Januar 2013.
135. 'Hepatocellular carcinoma: combination therapies'. Grand round, hospital Beaujon. Paris. March 2013.
136. 'Risque carcinologique de la MASH'. Journée d'hépatologie. Lyon. Juin 2013.
137. 'Hepatocellular Carcinoma'. SGGSSG Annual Meeting. Basel. September 2013.
138. 'Volkskrankheit Fettleber Risque carcinologique de la MASH'. Tag der Leber. Aarau. September 2013.
139. 'New generation of DAAs for the treatment of chronic hepatitis C'. 10th International Meeting on Therapy in Liver Diseases. Barcelona. September 2013.
140. 'Management of patients with NAFLD'. Workshop. EASL Masterclass. Bordeaux. November 2013.

141. 'HCC: what are the treatment options?' 1st Swiss Hepatology Postgraduate Course. Wolfsberg. November 2013.
142. 'Beyond cyclosporine: role of mTOR inhibitors'. Symposium – 30 years cyclosporine. Zürich. November 2013.
143. 'HCC: combination local-systemic therapies'. EASL Monothematic Conference. Geneva. February 2014.
144. 'The ABC of viral Hepatitis'. UEG Summer school. Prague. June 2014.
145. 'Directly acting antivirals for the treatment of hepatitis C: key messages from phase III trials'. Swiss Society for Infectious Diseases. Aarau. August 2014.
146. 'TACE: Who, When, How and How to evaluate?' HCC Day. Lausanne. September 2014.
147. 'Liver Cancer in Metabolic Diseases'. UEG Single Topic Conference. Birmingham 2014.
148. 'Impact of Lifestyle on NAFLD'. UEG Annual Meeting. Wien. October 2014.
149. 'Hepatocellular carcinoma: what is new in 2014'. UEG Annual Meeting. Wien. October 2014.
150. 'HCC cohort'. HCC Day. Zürich. January 2015.
151. 'Liver cancer in NAFLD: magnitude of the problem'. ILC EASL Annual Meeting. Wien. April 2015.
152. 'Physical activity and HCC'. EASD EASL study Group. Birmingham. May 2015.
153. 'Metabolic aging and the liver'. Swiss HIV Cohort Workshop. Basel. June 2015.
154. 'HCC Screening'. Preceptorship. Bern. June 2015.
155. 'Transarterial Chemoembolisation: what is the best protocol?' Viral Hepatitis Congress. Frankfurt. September 2015.
156. 'UEG 2015: Liver Summary'. Swiss Perspectives. Barcelona. October 2015.
157. 'Clinical Diagnosis and Staging of Intrahepatic Cholangiocarcinoma'. Annual meeting AASLD. San Francisco. November 2015.
158. 'New therapies for hepatitis B and C'. SGPGHE/SSGHNP Annual meeting. Bern. November 2015.
159. 'Nicht-alkoholische Steatohepatitis: neuer Hauptrisikofaktor des hepatozellulären Karzinoms'. Hepatologie State of the art 2015. Freiburg in Breisgau. November 2015.
160. 'Women and liver diseases. Alcohol and autoimmunity'. Swiss Hepatology Graduate Course. Wolfsberg. November 2015.
161. 'Liver transplantation: a changing world'. Swiss Transplantation Society. 14th Annual Meeting. February 2016.
162. 'Tests hépatiques perturbés, que faire?' Demi-journée de formation continue. Société Neuchâtoise de médecine. Neuchâtel. Mars 2016.
163. 'Treatment of NASH'. Falk Symposium. Gut Liver Interactions: from IBD to NASH. Innsbruck. March 2016.
164. 'HCC. Liver biopsy from the clinician perspective'. International Liver Meeting. Annual Meeting EASL. Barcelona. April 2016.
165. 'HCC and metabolomic'. Meeting del Martedì. Padova. April 2016.
166. 'Predicting outcomes in NASH'. EASL single topic conference 'NASH beyond the acronym'. Riga. May 2016.
167. 'HCC in NAFLD'. Meeting of the Czech Hepatology Society. Karlovy Vary. May 2016.
168. 'Hépatite C: quand il ne faut pas perdre le foie'. Fachsymposium 2016. Biel. June 2016.
169. 'Lifestyles and HCC'. Paris NASH Symposium. Paris. June 2016.
170. 'Hepatocellular carcinoma'. Annual Meeting Swiss Society of Gastroenterology. Interlaken. September 2016.
171. 'Bern HCC Cohort'. Seminario: Terapia del carcinoma epatocellulare in stadio intermedio-avanzato. Lugano. September 2016.
172. 'UEG 2016: Liver Summary'. Swiss Perspectives. UEG. Vienna. October 2016.

173. 'Non-invasive diagnosis of NASH'. UEG. Vienna. October 2016.
174. 'Liver nodule in cirrhotic patient'. UEG. Vienna. October 2016.
175. 'Carcinome hépatocellulaire. Mis à jour 2016-17'. Course de formation postgraduée et continue en médecine interne. Neuchâtel. Novembre 2016.
176. 'NASH für den Rheumatologen'. Fortbildungstagung Schweizerische Gesellschaft für Rheumatologie. Bern. Januar 2017.
177. 'State of the Art in Hepatitis C'. 15th Annual Meeting of the Swiss Transplantation Society. Thun. January 2017.
178. 'Current and future therapeutic approaches to NAFLD/NASH'. EASL ILC. Amsterdam. April 2017.
179. 'General Hepatology including tumors and liver transplantation'. EASL ILC. Amsterdam. April 2017.
180. 'NASH: Nouvelles cibles thérapeutiques'. 22^{ème} journée d'hépatologie et de transplantation. Lyon. Juin 2017.
181. 'What are the relevant results in the field of liver diseases'. UEG Summer School. Prag. June 2017.
182. 'Impact of macronutrient constituents of diet on NASH phenotypes and outcomes'. Paris NASH. Paris. July 2017.
183. 'HCC resection vs. transplantation'. Grand round. Claraspital. September 2017.
184. 'NASH'. Tag der Leber. SASL. Thun. October 2017.
185. 'Assessment of liver function in advanced chronic liver disease'. 25th UEG week. Barcelona. October 2017.
186. 'UEG 2017: Liver Summary'. Swiss Perspectives. UEG. Barcelona. October 2017.
187. 'NASH as a fertile soil for HCC'. EASL NASH summit. Geneva. November 2017.
188. 'HCC in NASH: When should we begin to screen and how'. Swiss Hepatology Graduate Course. Wolfsberg. November 2017.
189. 'Prognosis of NASH'. Paris Hepatology Conference. Paris. January 2018.
190. 'HCC in NASH: When should we begin to screen and how'. Global NASH summit. London. February 2018.
191. 'The changing epidemiology of HCC'. EASL HCC Summit. Geneva. March 2018.
192. 'Mitochondria dysfunction in NASH'. 7^{ème} colloque génomique fonctionnelle du foie. Lyon. March 2018.
193. 'Future NASH diagnostics:overcoming the bottleneck'. Genfit Symposium. ILC. Paris. April 2018.
194. 'HCC in non-cirrhotic liver'. Grand round. EASL Annual Meeting. ILC. Paris. April 2018.

Pregraduate and postgraduate teaching responsibilities:

'Hepatobiliary pathophysiology course'. (16 hours/year) School of Dietetics. 1999-2003.

'Pharmacology course'. (14 hours/year) School of Dentistry. 1999-2012.

Problem-based learning, Medical school first year. Tutor bloc 'Cell factory' 3.2001-5.2001

Problem-based learning, Medical school second year. Tutor bloc 'Gastrointestinal and renal physiology' (32 hours/year) 2002-2013.

Responsible for block 'Gastrointestinal and renal physiology' 3rd year of medical school 2010-ongoing.

Formation postgraduée en hépatologie/discussion de cas. Hôpital cantonal de Neuchâtel. 3 x 2 hours/year. 2005-ongoing.

Professional memberships:

American Association for the Study of Liver Disease (Fellow)

American Gastroenterology Association (Fellow)

American College of Gastroenterology

European Association for the Study of the Liver

Swiss Association for the Study of the Liver

Schweizerische Gesellschaft für Gastroenterologie und Hepatologie

Schweizerische Gesellschaft für Zellbiologie, Molekularbiologie und Genetik

International Liver Cancer Association (founding member)

Miscellaneous scientific functions

Associate Editor of Liver International (2008-2009), Journal of Hepatology (2009-2013), Hepatology, section Highlights (2013-2017), Journal of Gastrointestinal and Liver Diseases (2014-ongoing), GUT (2017-ongoing)

Member of the Editorial Board of the Journal of Hepatology (2003-2009), Clinical Science (2007-), World Journal of Gastroenterology (2006-2009)

Member of scientific committee of the **European Association for the Study of the Liver (EASL)** 2003-2006

Member of International Relations Committee of the American Association for the Study of the Liver (AASL) 2006-2009

Member of the Governing Board of the European Association for the Study of the Liver (EASL) Education Councillor 2011-2015

Member of the United European Gastroenterology (UEG) Educational committee 2011-2015

Reviewer of manuscripts submitted to the following scientific journals

American Journal of Physiology, American Journal of Transplantation, Cancer Research, Clinical Cancer Research, Clinical Gastroenterology and Hepatology, Expert Opinion on Investigational Drugs, Gastroenterology, Gut, Hepatology, Journal of Hepatology, Journal of Pathology, Liver International, Liver Transplantation, JPET, PlosOne, World Journal of Gastroenterology.

Project Reviewer of the following scientific institutions:

Swiss National Science Foundation

Schweizerische Stiftung für Alkoholforschung

Agence Nationale de la Recherche (France)

Canadian Liver Foundation

Research Foundation Flanders

Dutch Digestive Foundation

Biotechnology and Biological Sciences Research Council

AERES (Agence d'Evaluation de la Recherche et de l'Enseignement Supérieur): évaluation de l'institut Cochin. Paris, décembre 2008.

AERES (Agence d'Evaluation de la Recherche et de l'Enseignement Supérieur): évaluation de la demande de création d'unité monothématique, mars 2009.

Président du comité d'évaluation – « Programme d'Actions Intégrées de Recherche : Carcinome Hépatocellulaire » - INCa 2009.

OncoSuisse

Fondation contre le cancer (Belgique)

High Council for the Evaluation of Research and Higher Education (France)

Secretary of the Swiss Association for the Study of the Liver (SASL) 2000-2004

Advisor of the Swiss Board of Experts for Viral Hepatitis

Member Arbeitsgruppe Lebertransplantation von Swisstransplant (STAL)

Member of the Swiss Transplantation Cohort

Member of the Audit group of the STAL

Meetings organization

Third Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2004.
Fourth Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2005.
Tag der Leber 2005. Bern. June 2005.
3rd European Club for Liver Cell Biology. Ittingen. June 2005.
5th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2006.
EASL School of Hepatology. Spineto. January 2006.
6th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2007.
Jahreskongress SGG/SGH/SASL. Lausanne. September 2007.
7th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2008.
EASL Monothematic Conference on hepatocellular carcinoma. Prague. June 2008.
8th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2009.
9th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2010.
1st Swiss HCC day. Bern. November 2010
10th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2011.
2nd Swiss HCC day. Bern. November 2011
11th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2012.
12th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2013.
Postgraduate Course on Liver Transplantation. ILC EASL Annual meeting. Barcelona. April 2013.
3rd Swiss HCC day. Bern. November 2013
13th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2014.
4th Swiss HCC day. Zürich. January 2014
EASL HCC summit. Geneva. February 2014.
UEG summer school. Prague. June 2014.
14th Hepatobiliary and Gastrointestinal Research Meeting. Vulpera. January 2015.
5th Swiss HCC day. Zürich. January 2015
Postgraduate Course on Metabolic Liver Disease. ILC EASL Annual meeting. Wien. April 2015.
UEG summer school. Prague. June 2015.
EASL Monothematic Conference on NASH. Riga. May 2016.
UEG summer school. Prague. June 2016.
UEG summer school. Prague. June 2017.

GCP Training:

Fortbildung GCP 3.4.2008

GCP for Investigators and Sub-Investigators 6.6.2011

Phase-Forward GCP Training 13.10.2011

GCP for Investigators: Advanced GCP and clinical research training course 3.11.2015

GCP for Investigators 23.11.2016

GCP for Investigators 14.12.2016

Principal Investigator

SASL #11: 'Treatment with Vitamin E and UDCA of patients with NASH, a placebo-controlled double blind study'

SASL #20: 'Treatment with Rosiglitazone of patients with NASH, a placebo-controlled double blind study'

S-TACE Study: 'Sorafenib in combination with TACE for hepatocellular carcinoma'.

Protocol SAKK 77/09 and SASL 30. A phase I open label/Phase II randomized, double-blind, multicenter trial investigating the combination of Everolimus and TransArterial ChemoEmbolisation (TACE) with doxorubicin in patients with hepatocellular carcinoma eligible for TACE.

Investigator in international clinical trials:

STORM trial (sorafenib adjuvant)

REACH trial (ramucirumab second line)

SAKK 77/09 (TACE with/without everolimus)

Bayer HCC 15982 (regorafenib), Bayer HCC 16553 (Refametinib)

METIV-HCC (tivantinib second line)

Boehringer Ingelheim trials 1241.21, 1220.3, 1220.5 1220.7, 1220.48

AbbVie chronic hepatitis C: Sapphire I, Pearl II, ENDURANCE-1, ENDURANCE-3

BMS chronic hepatitis C: AI447-029

Gilead chronic hepatitis C: Solar-2

Investigator (with participation at multiple clinical studies)

Swiss Hepatitis Cohort

SASL

FLIP (FP-7)

Direct supervision of Ph.D. Students

1. F. Magnino (1998-2001): IP₃-receptor and calcium signalling in the liver.
Bürigi Preis 2002
2. L. Wang (2000-2004) : Regulation of connexin and CREB in biliary epithelial cells
3. D. Semela (2002-2006): Anti-angiogenesis to treat hepatocellular carcinoma in animal models.
Scholarship from the Swiss Association for Gastroenterology and Hepatology, 2002.
4. Anne-Christine Piguet (2004-2008): PTEN/mTOR Pathway and experimental hepatocellular carcinoma.
Scholarship from the Swiss Association for Gastroenterology and Hepatology, 2007.
Bürigi Preis 2008.
5. C. Hora (2008-2014) PTEN/mTOR Pathway and experimental hepatocellular carcinoma.
6. Raviprasadh Rajasekaran (2013-ongoing): Partners of Hint2

Mentoring of Ph.D. Students

1. He Liu (2008-): The role of Atg5 in human cutaneous melanoma (PI: H-U. Simon).
2. Andrea Schmitz (2008-2011): In vitro investigations of phase I biotransformation of ketamine in equines and canines (PI: M. Mevissen)
3. Lorianne Vorlet-Fawer: Mechanisms of impaired IP3K/Akt survival pathway involved in hippocampal neuronal apoptosis caused by pneumococcal meningitis (PI: S. Christen)
4. Tamara Horn (2009 -): IP₃-induced calcium release in atrial myocytes (PI: M. Egger)
5. Daniel Gutierrez (2009 -): Phosphorylation of ryanodine receptor, changes in its cytoplasmic and ER calcium sensitivity (PI E. Niggli)
6. Janine Hensel (2009 - 2014): Reciprocal interaction of cancer cells and bone marrow stroma in osteolytic bone metastasis (PI: G. Thalmann)
7. Simone Portmann (2010 - 2014): Targeting Sirt1 to impair the growth of primary liver cell tumors (PI: D. Stroka).
8. Valentina Carta (2010-2014): A novel open channel blocker of GABA_A receptor (PI: E. Sigel).

M.D. Students (thesis)

1. M. Kolev (2004-2009): Anti-angiogenesis to treat hepatocellular carcinoma in animal models
2. C. Hora (2005-2008): Role of CTGF in progression of chronic hepatitis C.
Scholarship from the Swiss Association for Gastroenterology and Hepatology, 2005
3. S. Generelli (2005-2008): Ion-selective microelectrode array for the detection of intracellular calcium activities in hepatocytes and cholangiocytes.
Scholarship from the Swiss Association for Gastroenterology and Hepatology, 2006
4. M. Balmer (2006-2008): Cytokines and adipokines in patients suffering from NASH treated with UDCA and vitamin E.
5. K. Sigrist (2006-2008): Effects of UDCA and vitamin E on apoptosis in patients with NASH.

- 6 C. Sgier (2008-2009): Effect of antiviral therapy on M30 assay in patients with chronic hepatitis C.
- 7 Lorenz Kuske (2010-2012): Epidemiological characteristics of the Swiss Hepatitis C Cohort patients with hepatocellular carcinoma.
- 8 Farah Al-Hasani (2012-2013): Factors affecting screening for hepatocellular carcinoma.
- 9 M. Richani (2013-2015): Role of guidelines in management of HCC
- 10 A. Gmür (2013-ongoing): Quality of life of patients affected with HCC
- 11 P. Kolly (2014-ongoing): Survival of patients affected with HCC
- 12 G. Aeby (2014-ongoing): Physical activity and HCC
- 13 Angélique Ndarugendamwo (2014-ongoing): OLT for HCC
- 14 Nathalie Caversaccio (2016-ongoing): Tissue factor and HCC
- 15 Silvio Nahmias (2017-ongoing):

Postdoctoral Trainee

1. Juliette Martin (2001-2003): Hint2 a novel human HIT protein. Scholarship from the Swiss Association for Gastroenterology and Hepatology, 2003.
2. Pamela Romanque (2007-2008)
3. Anne-Christine Piguet (2008-): role of mTOR on hepatocarcinogenesis in mice lacking hepatocellular PTEN.
4. Juliette Martin (2006-2008): Hint2 a novel human HIT protein. Fellowship from the European Association for the Study of the Liver, 2006.
5. Uttara Saran (2014-2016): Effects of physical activity on hepatocellular carcinoma.
6. Maria Guarino (2017): Activity on hepatocellular carcinoma.

External expert for PhD thesis

1. Valérie Serrière-Lanneau. 'Distribution du récepteur de la vasopressine dans le lobule hépatique'. Université Paris. Juillet 2003
2. Ludovic Menard. 'Rôle de la reptine dans le carcinoma hépatocellulaire'. Université Bordeaux. Décembre 2007
3. Yvan Borbath. 'Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models'. Université Catholique de Louvain. April 2009
4. Antonino Sgroi. 'Hepatocyte transplantation and cytokine therapy: future treatments for acute liver failure'. Université de Genève. November 2011
5. Hervé Lerat. 'Un virus, des souris et des hommes'. Jury pour l'obtention du diplôme HDR. Paris. Octobre 2014
6. Mohamed Imache. 'Mécanismes moléculaires de l'activation d'Akt par les protéines du VHC et implications dans l'hépatocarcinogenèse viro-induite'. Thèse pour l'obtention du grade de Docteur de l'université Paris-Est Créteil. Janvier 2016.

7. Pierre Glaudes. 'Hémodynamique, Interaction, Fibrose, Invasivité tumorale Hépatique et Digestive'. Campagne d'évaluation des entités de recherche de la vague B. Angers. Janvier 2016
8. Diana Hide Alförez. 'Advances in ischemia and reperfusion injury: effects on liver microcirculation and therapeutic strategies for sinusoidal protection'. Barcelona. April 2016
9. Cédric Coulouarn. 'L'échelle du génome et de l'épigénome les mécanismes moléculaires de l'oncogenèse en prenant pour modèles d'étude les cancers primitifs du foie'. Thèse pour l'obtention du diplôme d'HDR. Angers. Janvier 2017

Other activities related to teaching

Mitglied Planungskommission Masterstudiengang Biomedical Sciences (BMS) 2005- 2011.

Mitglied der Betreuungskommission 'Biologische Systeme' Graduate School for Cellular and Biomedical Sciences. University of Bern. 2008-2010

Member of the Jury. Tag der Klinischen Forschung. Bern. 2010.

Clinical Research Experience:

Principal Investigator of 2 published investigator-initiated studies

Co-principal investigator for numerous SASL and SAKK studies

Sub-investigator for numerous pharma-sponsored trials

Training in GCP (SwPP/SGPM 2009)

LIST OF PUBLICATIONS

A. Original Articles: (Peer Review)

		*IF	**Ranking
1.	P. Jolliet, C. Magnin, J-F. Dufour , PF. Unger. Approche de l'embolie pulmonaire massive avec état de choc. Journal européen des urgences. 1990;4:245-248.		
2.	J-F. Dufour , F. Waldvogel. Les méningites de l'adulte à Genève. Revue de 257 cas. Schweiz. Wochenschrift. 1991; Supplementum 35:1-37.	0.283	
3.	J-F. Dufour , C. Stoupis, F. Lazeyras, P. Vock, F. Terrier, J. Reichen. Alterations in hepatic fructose metabolism in cirrhotic patients demonstrated by dynamic P-31 spectroscopy. Hepatology 1992;15:835-842.	4.073	
4.	J-F. Dufour , J. Reichen. Hepatic accumulation of lysosomes with defective transcytotic vesicular pathways in cirrhotic rat liver. Hepatology 1992;16:997-1006.	4.073	
5.	F. Shulman, R. Montali, M. Bush, S. Citino, L. Tell, J. Ballou, T. Hudson, M. St-Pierre, J-F. Dufour , Z. Gatmaitan, I. Arias, F. Johnson. Dubin-Johnson-like syndrome in Golden Lion Tamarins (<i>Leontopithecus rosalia rosalia</i>). Vet. Pathol. 1993;30:491-498.	0.682	
6.	J-F. Dufour , A. Zimmermann, J. Reichen. Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages. J. Hepatol. 1994;20:524-530.	3.154	
7.	J-F. Dufour , T. Turner, I. Arias. Nitric oxide blocks canalicular contraction by inhibiting InsP ₃ -dependent Ca ²⁺ mobilization. Gastroenterology 1995;108:841-849.	8.203	
8.	M. St.-Pierre, J-F. Dufour , I. Arias. Stimulation of bile acid independent bile flow with bromo-cyclic guanosine monophosphate. Hepatology. 1996;24:1487-1491.	6.040	
9.	J-F. Dufour , Karim A. Fawaz, E. Libby. Botulinum toxin injection for secondary achalasia with esophageal varices. Gastr. Endosc. 1997;45:191-193.	2.770	
10.	J-F. Dufour , MM. Kaplan. Methotrexate and acute liver toxicity. Letter. N. Engl. J. Med. 1996;335:898.	24.834	
11.	M. St.-Pierre, J-F. Dufour , I. Arias. Disruption of actin organization by Cytochalasin D does not impair biliary secretion of organic anions. Hepatology 1997;25:970-975.	5.849	
12.	J-F. Dufour , I. Arias and T. Turner. IP ₃ and Ca ²⁺ regulate the Ca ²⁺ channel function of the hepatic IP ₃ receptor. J. Biol. Chem. 1997;272:2675-2681.	6.963	
13.	J-F. Dufour , R. DeLellis, MM. Kaplan. Reversibility of hepatic fibrosis in autoimmune hepatitis? Ann Int Med. 1997;127:981-984.	12.047	
14.	M. St.-Pierre, T. Schlenker, J-F. Dufour , D. Jefferson, J.G. Fitz, I. Arias. Stimulation of cGMP production by natriuretic peptide and effect on Cl ⁻ permeability in human biliary cells. Gastroenterology. 1998;114:782-790.	10.330	

15.	J-F. Dufour , R. DeLellis, MM. Kaplan. Regression of hepatic fibrosis in hepatitis C with long term interferon alpha therapy. <i>Dig Dis Sci.</i> 1998;43:2573-6.	1.972	
16.	C. Seiler, J-F. Dufour , E. Renner, M. Schilling, M. Büchler, P. Bischoff, J. Reichen. Primary liver disease as a determinant for acute rejection after liver transplantation. <i>Langenbeck's Arch Surg</i> 1999;384:259-263.	1.175	
17.	J-F. Dufour , M. Lüthi, M. Forestier, F. Magnino. Expression of inositol 1,4,5-trisphosphate receptors isoforms in rat biliary cirrhosis. <i>Hepatology.</i> 1999;30:1018-26.	7.334	
18.	F. Magnino, M. St-Pierre, M. Lüthi, M. Hilly, J-P. Mauger, J-F. Dufour . Expression of hepatic intracellular calcium channels and pumps after partial hepatectomy in rat. <i>Mol Cell Biol Res Com.</i> 2000;3:374-9.		
19.	L. Mery, F. Magnino, K. Schmidt, K.H. Krause, J-F. Dufour . Alternative splice variants of hTrp4 differentially interact with the C-terminal of the inositol 1,4,5-trisphosphate receptors. <i>FEBS Letters.</i> 2001;487:377-83.	3.644	
20.	C. Redaelli, M. Wagner, Y-H. Tien, L. Mazzucchelli, P. Stahel, M. Schilling, J-F. Dufour . 1α , 25 dihydroxychole-calciferol reduces rejection and improves survival in rat liver allografts. <i>Hepatology.</i> 2001;34:926-34.	8.096	
21.	J-F. Dufour , D. Pratt. Alagille syndrome with colonic polyposis. <i>Am J Gastroenterology.</i> 2001;96:2775-7.	3.549	
22.	C. Redaelli, M. Wagner, L. Krahenbuhl, B. Gloor, M. Schilling, J-F. Dufour , M. Büchler. Liver Surgery in the Era of Tissue-preserving Resections: Early and Late Outcome in Patients with Primary and Secondary Hepatic Tumors. <i>World J Surg.</i> 2002;26:1126-32.	1.644	
23.	C. Redaelli, J-F. Dufour , M. Wagner, M. Schilling, M. Hüsler, L. Krähenbühl, M. Büchler, J. Reichen. Preoperative Galactose Elimination Capacity predicts morbidity and survival after hepatic resection. <i>Ann of Surgery</i> 2002;235:77-85.	6.674	
24.	F. Magnino, K. Schmidt, L. Mery, J-F. Dufour . Rat inositol 1,4,5-trisphosphate receptor isoform 2 interacts with itself in its C-terminal portion and upstream of the first transmembrane domain. <i>Eur J Biochem.</i> 2001;268:5981-8.	2.849	
25.	J. Sneyd, J-F. Dufour . A dynamic model for the inositol tri-phosphate receptor. <i>Proc. Natl. Acad. Sci USA.</i> 2002;99:2398-403.	10.700	
26.	B. Helbling, I. Stamenic, F. Viani, J-J. Gonvers, J-F. Dufour , J. Reichen, G. Cathomas, M. Steuerwald, J. Borovicka, M. Sagmeister, E. Renner. Interferon and Amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. <i>Hepatology.</i> 2002;35:447-54.	9.825	
27.	C. Redaelli, Y-H. Tian, T. Schaffner, M. Ledermann, H. Baer, J-F. Dufour . Extended preservation of rat liver graft by induction of heme oxygenase-1. <i>Hepatology.</i> 2002;35:1082-92.	9.825	

28.	H-P. Bode, L. Wang, D. Cassio, M. F. Leite, M. St-Pierre, K. Hirata, K. Okaszki, M. Sears, P. Meda, M. Nathanson, J-F. Dufour . Expression and regulation of gap junctions in rat cholangiocytes. <i>Hepatology</i> . 2002;36:631-49.	9.825	
29.	K. Hirata, J-F. Dufour , K. Shibao, R. Knickelbein, A. O'Neill, H-P. Bode, D. Cassio, M. St-Pierre, N. LaRusso, M. F. Leite, M. Nathanson. Regulation of Ca ²⁺ signaling in rat bile duct epithelia by IP ₃ receptor isoforms. <i>Hepatology</i> . 2002;36:284-96.	9.825	
30.	L. Mery, B. Strauss, J-F. Dufour , K. H. Krause, M. Hoth. The subcellular localization of the cation channel hTRP4 depends on its interaction with EBP50 and the actin-binding proteins of the ERM family in HEK293 cells. <i>J Cell Sci</i> . 2002;115:3497-3508.	6.954	
31.	J-F. Dufour , M. Zimmermann, J. Reichen. Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. <i>J Hepatol</i> . 2002;37:748-52.	4.974	
32.	H-P. Dinkel, K. Wittchen, H. Hoppe, J-F. Dufour , A. Zimmermann, J. Triller. Transjugular liver core biopsy: indications, results, and complications. <i>Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr</i> . 2003;175:1112-9.	1.786	0.602
33.	A. Krauskopf, P. Lhote, M. Mutter, J-F. Dufour , U. Ruegg, T. Buetler. Vasopressin type 1A receptor upregulation by cyclosporin A in vascular smooth muscle cells is mediated by superoxide. <i>J Biol Chem</i> . 2003;278:41685-90.	6.482	0.885
34.	J. Hovinga, M. Solenthaler, J-F. Dufour . Congenital dyserythropoietic anemia type II (HEMPAS) and hemochromatosis: a report of 2 cases. <i>Eur J Gastroenterol Hepatol</i> . 2003;15:1141-7.	1.578	0.489
35.	J-F. Dufour , H-P. Dinkel, A. Zimmermann. Image of the month. <i>Gastroenterology</i> . 2003;125:1010.	12.718	1.000
36.	Y. Vashist, D. Semela, J-F. Dufour . Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. <i>Med Hypothesis</i> . 2004;62:82-85.	0.607	0.155
37.	C. Redaelli, D. Semela, F. Carrick, M. Ledermann, D. Candinas, B. Sauter, J-F. Dufour . Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. <i>J Hepatol</i> 2004;40:305-312.	4.816	0.935
38.	J. Sneyd, M. Falcke, J-F. Dufour , C. Fox. A comparison of three models of the inositol trisphosphate receptor. <i>Prog Biophys Mol Biol</i> . 2004;85:121-40.	4.551	0.875
39.	A. De Gottardi, F. Touri, C. Maurer, A. Perez, O. Maurhofer, G. Ventre, C. Bentzen, E. Niesor, J-F. Dufour . The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. <i>Dig Dis Sci</i> . 2004;49:982-9.	1.427	0.370
40.	M. St-Pierre, T. Stallmach, A. Freimoser, A. Grunschöber, J-F. Dufour , M. Serrano, J. Marin, Y. Sugiyama, P. Meier. Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. <i>Am J Physiol Regul Integr Comp Physiol</i> . 2004;287:R1505-16.	3.405	0.808

41.	O. Guenat, J-F. Dufour , P.D. van der Wal, W.E. Morf, N.F. de Rooij, M. Koudelka-Hep. Microfabrication and characterization of an ion-selective microelectrode array platform. <i>Sensors and Actuators B:Chemical</i> 2005;105:65-73.	2.646	0.814
42.	A. Muzzi, G. Leandro, L. Rubbia-Brandt, R. James, O. Keiser, R. Malinverni, J-F. Dufour , B. Helbling, A. Hadengue, J-J. Gonvers, B. Mullhaupt, A. Cerny, M. Mondelli, F. Negro. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patient. <i>J hepatol</i> 2005;42:41-6.	4.931	0.913
43.	H. Chtioui, A. Zimmermann, J-F. Dufour . Unusual evolution of posterior reversible encephalopathy syndrome (PRES) one year after liver transplantation. <i>Liver Transplantation</i> . 2005;11:588-90.	4.447	0.986
44.	L. Wang, A-C. Pigué, K. Schmidt, T. Tordjmann, J-F. Dufour . Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition. <i>Hepatology</i> . 2005;41:1241-51.	9.792	0.978
45.	J. Martin, F. Magnino, K. Schmidt, A-C. Pigué, J-S. Lee, D. Semela, M. V. St-Pierre, A. Ziemiecki, D. Cassio, C. Brenner, S. Thorgeirsson, J-F. Dufour . Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. <i>Gastroenterology</i> . 2006;130:2179-88.	12.457	1.000
46.	J-F. Dufour , C. Oneta, J-J. Gonvers, F. Bihl, A. Cerny, J-M. Cereda, J-F. Zala, B. Helbling, M. Steuerwald, A. Zimmermann and the SASL. Randomized placebo-controlled trial testing ursodeoxycholic acid and vitamin E in non-alcoholic steatohepatitis. <i>Clin Gastro Hep</i> 2006;4:1537-1543.	0.91892	0.919
47.	D. Semela, A-C. Pigué, M. Kolev, K. Schmitter, R. Hlushchuk, V. Djonov, C. Stoupis, J-F. Dufour . Vascular remodelling and anti-tumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. <i>J Hepatol</i> 2007;46:840-8.	6.642	0.94
48.	Y. Banz, D. Inderbitzin, CA. Seiler, SW: Schmid, J-F. Dufour , A. Zimmermann, P. Mohacsi, D. Candinas. Bridging hyperacute liver failure by ABO-incompatible auxiliary partial orthotopic liver transplantation. <i>Transplant Int</i> . 2007;20:722-7.	2.300	0.799
49.	H. Chtioui, D. Semela, M. Ledermann, A. Zimmermann, J-F. Dufour . Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. <i>Liver Int</i> . 2007;27:764-71.	2.559	0.62
50.	J. Plock, S. Frese, A. Keogh, S. Bisch-Knaden, E. Ayuni, N. Corazza, C. Weikert, S. Jakob, D. Erni, J-F. Dufour , T. Brunner, D. Candinas, D. Stroka. Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver. <i>J Hepatol</i> . 2007;47:538-45.	6.642	0.94
51.	P. Roth, C. Hammer, A-C. Pigué, M. Ledermann, J-F. Dufour , E. Waelti. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. <i>J Drug Target</i> . 2007;15:623-31.	2.030	0.475

52.	C. Hora, F. Negro, G. Leandro, CM Oneta, L. Rubbia-Brandt, B. Muellhaupt, B. Helbling, R. Malinverni, J-J. Gonvers, J-F. Dufour , the Swiss Hepatitis C Cohort Study Group. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. <i>Liver Int.</i> 2008;28:370-6.	2.908	0.655
53.	A-C. Piguet, D. Semela, A. Keogh, L. Wilkens, D. Stroka, C. Stoupis, M.V. St-Pierre, J-F. Dufour . Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. <i>J Hepatol</i> 2008;49:78-87.	7.056	0.927
54.	V. Roh, A. Laemmle, U. Von Holzen, D. Stroka, J-F. Dufour , K. Hunt, D. Candinas, S. Vorburger. Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma. <i>Cancer Gene Ther.</i> 2008;15:636-44.	3.005	0.754
55.	S. Lenglet, F. Antigny, L. Vetterli, J-F. Dufour , MF Rossier. Hint2 is expressed in the mitochondria of H295R cells and is involved in steroidogenesis. <i>Endocrinology.</i> 2008;149:5461-9.	4.945	0.796
56.	B. Helbling, K. Overbeck, J-J. Gonvers, R. Malinverni, J-F. Dufour , J. Borovicka, M. Heim, A. Cerny, F. Negro, S. Bucher, M. Rickenbach, E. Renner, B. Muellhaupt. Host- rather than Virus-Related Factors Reduce Health-Related Quality of Life in Hepatitis C Virus Infection. <i>Gut.</i> 2008;57:1597-603.	9.766	0.964
57.	S. Dinges, I. Morard, M. Heim, J-F. Dufour , B. Müllhaupt, E. Giostra, PA. Clavien, G. Mentha, F. Negro; Swiss Association for the Study of the Liver (SASL 17). Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. <i>Transpl Infect Dis.</i> 2009;1:33-9.	2.063	0.5
58.	ML. Balmer, K. Siegrist, A. Zimmermann, J-F. Dufour . Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with non-alcoholic steatohepatitis (NASH). <i>Liver International.</i> 2009;8:1184-8.	2.987	0.734
59.	PY. Bochud, T. Cai, K. Overbeck, M. Bochud, J-F. Dufour , B. Müllhaupt, J. Borovicka, M. Heim, D. Moradpour, A. Cern, R. Malinverni, P. Francioli, F. Negro; Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. <i>J. Hepatol.</i> 2009; 51:655-66.	7.818	0.953
60.	AC. Piguet, D. Stroka, A. Zimmermann, J-F. Dufour . Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. <i>Clinical Science.</i> 2009;118:401-410.	3.982	0.8
61.	M. Seitz, S. Reichenbach, B. Möller, M. Zwahlen, PM. Villiger, J-F. Dufour . Hepatoprotective effect of TNF-a blockade in psoriatic arthritis: a cross-sectional study. <i>Ann Rheum Dis.</i> 2010;69:1148-50.	9.082	1
62.	C. Sgier, B. Müllhaupt, T. Gerlach, D. Moradpour, F. Negro, PJ. Malé, MH. Heim, R. Malinverni, A. Cerny, J-F. Dufour . Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. <i>J Viral hepatitis.</i> 2010;17:845-50.	3.502	0.743
63.	H. Chtioui, Olivier Mauerhofer, Beatrice Günther, J-F. Dufour . Macro-AST in an asymptomatic young patient. <i>Annals of Hepatology.</i> 2010;9:93-95.	1.867	0.357

64.	A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. di Julio, T. Mueller, M. Bochud, M. Battegay, E. Bernasconi, J. Borovicka, T. Calandra, S. Colombo, A. Cerny, J-F. Dufour , H. Furrer, H.F. Günthardt, M. Heim, B. Hirschel, R. Malinverni, D. Moradpour, B. Muellhaupt, A. Witteck, J. Beckman, T. Berg, S. Bergman, F. Negro, A. Telenti, P-Y. Bochud, and the Swiss HCV and HIV Cohort Studies. Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genomewide Association Study. <i>Gastroenterology</i> . 2010;138:1338-45.	12.032	1
65.	K. Overbeck, J-F. Dufour , B. Müllhaupt, B. Helbling, J. Borovicka, R. Malinverni, M. Heim, D. Moradpour, A. Cerny, M. Rickenbach, F. Negro. Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. <i>Swiss Med Wkly</i> . 2010; 140:146-52.	1.823	0.711
66.	ML. Blamer, J. Joneli, A. Schoepfer, F. Stickel, W. Thormann, J-F. Dufour . Significance of serum adiponectin in patients with chronic liver diseases. <i>Clin Sci</i> . 2010;119:431-6.	4.613	0.846
67.	H. Chtioui, O. Maurhofer, B. Günther, J-F. Dufour . Macro-AST in an asymptomatic young patient. <i>Ann Hepatol</i> 2010;):93-95.	1.867	0.357
68.	J-F. Dufour , H. Hoppe, M. Heim, B. Helbling, O. Maurhofer, Z. Szucs-Farkas, R. Kikuth, M. Borner, D. Candinas, B. Saar. Continuous administration of sorafenib in combination with transarterial-chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. <i>The Oncologist</i> . 2010;15:1198-204.	5.826	0.881
69.	J. Martin, P. Romanque, O. Maurhofer, K. Schmitter, G. Ferrand, J-F. Dufour . Ablation of the tumor suppressor Hint1 is protective against ischemia reperfusion injury. <i>Hepatology</i> . 2011;53:243-52.	11.665	0.986
70.	C. Hora, P. Romanque, J-F. Dufour . Effect of Sorafenib on murine liver regeneration. <i>Hepatology</i> . 2011;53:577-86.	11.665	0.986
71.	A-C. Piguet, B. Saar, R. Hlushchuk, MV. St-Pierre, PM. McSheehy, V. Radojevic, M. Afthinos, L. Terraciano, V. Djonov, J-F. Dufour . Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. <i>Mol Cancer Ther</i> . 2011;10:1007-17.	5.226	0.856
72.	T. Cai, J-F. Dufour , B. Muellhaupt, T. Gerlach, M. Heim, D. Moradpour, A. Cerny, R. Malinverni, V. Kaddai, M. Bochud, F. Negro, P-Y. Bochud. Viral genotype-specific role of PNPLA3, PPARG, MTP, and IL28B in hepatitis C virus-associated steatosis. <i>J. Hepatology</i> . 2011;55:529-535.	9.264	0.959
73.	AD. Paterson, O. Maurhofer, D. Beyoglu, C. Lanz, KW Krausz, T. Pabst, FJ, Gonzalez, J-F. Dufour , J. Idle. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomic and lipid profiling. <i>Cancer Res</i> . 2011;71:6590-600.	7.856	0.941
74.	CM. Lange, Z. Kutalik, K. Morikawa, S. Bibert, A. Cerny, G. Dollenmaier, J-F. Dufour , T. Gerlach, MH. Heim, R. Malinverni, B. Müllhaupt, F. Negro, D. Moradpour, PY. Bochud; the Swiss Hepatitis C Cohort Study Group. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon- α and ribavirin therapy. <i>Hepatology</i> . 2012;55:1038-47.	12.003	0.986

75.	PY. Bochud, S. Bibert, Z. Kutalik, E. Patin, J. Guergnon, B. Nalpas, N. Goossens, L. Kuske, B. Müllhaupt, T. Gerlach, MH. Heim, D. Moradpour, A. Cerny, R. Malinverni, S. Regenass, G. Dollenmaier, H. Hirsch, G. Martinetti, M. Gorgiewski, M. Bourlière, T. Poynard, I. Theodorou, L. Abel, S. Pol, J-F. Dufour , F. Negro; on behalf of the Swiss Hepatitis C Cohort Study Group the ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. <i>Hepatology</i> . 2012;55:384-94.	12.003	0.986
76.	K. Baur, JC. Mertens, J. Schmitt, R. Iwata, B. Stieger, P. Frei, B. Seifert, HA. Bischoff Ferrari, A. von Eckardstein, B. Müllhaupt, A. Geier; Swiss Hepatitis C Cohort Study Group (incl. J-F. Dufour). The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. <i>Antivir Ther</i> . 2012;17:541-7.	3.073	0.724
77.	W. Sieghart, M. Pinter, B. Dauser, N. Rohr-Udilova, A-C. Piguet, G. Prager, H. Hayden, HP. Dienes, J-F. Dufour , M. Peck-Radosavljevic M. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. <i>J. Hepatol</i> . 2012;57:592-9.	9.858	0.945
78.	F. Girardin, Y. Daali, M. Gex-Fabry, M. Rebsamen, P. Roux-Lombard, A. Cerny, F. Bihl, J. Binek, D. Moradpour, F. Negro, J. Desmeules; Swiss Hepatitis C Cohort Study Group (incl. J-F. Dufour). Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. <i>J Viral Hepat</i> . 2012;19:568-73.	3.082	0.721
79.	C. Lange, S. Bibert, Z. Kutalik, P. Burgisser, A. Cerny, J-F. Dufour , A. Geier, T. Gerlach, M. Heim, R. Malinverni, F. Negro, S. Regenass, K. Badenhoop, J. Bojunga, C. Sarrazin, S. Zeuzem, T. Müller, T. Berg, PY. Bochud, D. Moradpour; Swiss Hepatitis C Cohort Study Group. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. <i>PLoS One</i> . 2012;7:e40159.	3.73	0.882
80.	E. Patin E, Z. Kutalik, J. Guergnon, S. Bibert, B. Nalpas, E. Jouanguy, M. Munteanu, L. Bousquet, L. Argiro, P. Halfon, A. Boland, B. Müllhaupt, D. Semela, J-F. Dufour , M. Heim, D. Moradpour, A. Cerny, R. Malinverni, H. Hirsch, G. Martinetti, V. Suppiah, G. Stewart, D. Booth, J. George, J. Casanova, C. Bréchet, C. Rice, A. Talal, I. Jacobson, M. Bourlière, I. Theodorou, T. Poynard, F. Negro, S. Pol, PY. Bochud, L. Abel; Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium, French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. . 2012;143:1244-1252.	12.821	1
81.	L. Kuske, A. Mensen, B. Müllhaupt, F. Negro, D. Semela, D. Moradpour, PJ. Malé, M. Heim, R. Malinverni, A. Cerny, J-F. Dufour ; Swiss Hepatitis C Cohort Study. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. <i>Swiss Med Wkly</i> . 2012 Aug 6;142:w13651.	1.821	0.682

82.	J. Martin, O. Maurhofer, N. Bellance, G. Benard, F. Graber, D. Hahn, A. Galinier, C. Hora, A. Gupta, G. Ferrand, H. Hoppeler, R. Rossignol, J-F. Dufour , MV. St-Pierre. Disruption of the histidine triad nucleotide-binding <i>hint2</i> gene in mice affects glycemic control and mitochondrial function. <i>Hepatology</i> . 2013;105:1268-75.	12.003	0.986
83.	AJ. van der Meer, BJ. Veldt, JJ. Feld, H. Wedemeyer, J-F. Dufour , F. Lammert, A. Duarte-Rojo, EJ. Heathcote, MP. Manns, L. Kuske, S. Zeuzem, WP. Hofmann, RJ. de Knegt, BE. Hansen, HL. Janssen. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. <i>JAMA</i> .2012;308:2584-93.	29.978	0.987
84.	M. Rau, F. Stickel, S. Russmann, C. Manser, P. Becker, M. Weisskopf, J. Schmitt, M. Dill, J-F. Dufour , D. Moradpour, D. Semela, B. Müllhaupt, A. Geier. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. <i>J Hepatol</i> . 2012;11.027. 2013;58:669-75.	9.858	0.945
85.	S. Majumder, AC. Piguet, J-F. Dufour , S. Chatterjee. Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. <i>EUR J Pharmacol</i> . 2013;705:86-95.	2.73	0.644
86.	D. Beyoğlu, S. Imbeaud, O. Mauerhofer, P. Bioulac-Sage, J. Zucman-Rossi, J-F. Dufour , JR. Idle. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. <i>Hepatology</i> . 2013;58:229-38.	11.711	0.962
87.	CM. Lange, S. Bibert, J-F. Dufour , C. Celleraï, A. Cerny, MH Heim, L. Kaiser, R. Malinverni, B. Müllhaupt, F. Negro, D. Semela, D. Moradpour, Z. Kutalik, PY. Bochud. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. <i>J Hepatol</i> . 2013;59:504-9.	10.59	0.949
88.	CM. Lange, D. Miki, H. Ochi, HD. Nischalke, J. Bojunga, S. Bibert, K. Morikawa, J. Gouttenoire, A. Cerny, J-F. Dufour , M. Gorgievski-Hrisoho, MH. Heim, R. Malinverni, B. Müllhaupt, F. Negro, D. Semela, Z. Kutalik, T. Müller, U. Spengler, T. Berg, K. Chayama, D. Moradpour, PY. Bochud. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. <i>PLoS One</i> . 2013;8:e64053.	3.057	0.836
89.	C. Erös de Bethlenfalva-Hora, JC. Mertens, AC. Piguet, J. Kettenbach, J. Schmitt, L. Terracciano, R. Weimann, J-F. Dufour , A. Geier. Radiofrequency Ablation Suppresses Distant Tumor Growth in a Novel Rat Model of Multifocal Hepatocellular Carcinoma. <i>Clin Sci (Lond)</i> . 2013;126:243.52.	4.996	0.879
90.	D. Ndiaye, M. Collado-Hilly, J. Martin, S. Prigent, J-F. Dufour , L. Combettes, G. Dupont. Characterization of the Effect of the Mitochondrial Protein Hint2 on Intracellular Ca(2+) dynamics. <i>Biophys J</i> . 2013; 105:1268-75.	3.632	0.761

91.	P. Frei, AK. Leucht, U. Held, R. Kofmehl, CN Manser, J. Schmitt, J. Mertens, M. Rau, K. Baur, T. Gerlach, F. Negro, M. Heim, D. Moradpour, A. Cerny, J-F. Dufour , B. Müllhaupt, A. Geier. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon- α and ribavirin in chronic hepatitis C virus patients. <i>Liver Int.</i> 2013;34:551-7.	4.47	0.846
92.	AJ. van der Meer, BJ. Veldt, JJ. Feld, H. Wedemeyer, J-F. Dufour , F. Lammert, A. Duarte-Rojo, MP. Manns, S. Zeuzem, WP. Hofmann, RJ de Knegt, BE. Hansen, HL. Janssen. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>J Viral Hepat.</i> 2013;21:568-77.	4.179	0.716
93.	YL. Liu, GL Patman, JB Leathart, A-C. Piguët, AD Burt, J-F. Dufour , CP Day, AK Daly, HL Reeves, QM Anstee. Carriage of the PNPLA3 rs738409C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. <i>J Hepatol.</i> 2014; 61:75-81.	4.122	0.81
94.	F. Al Hasani, M. Knoepfli, A. Gemperli, A. Kollar, V. Banz, J. Kettenbach, P. Jüni, J-F. Dufour . Factors affecting screening for hepatocellular carcinoma. <i>Ann Hepatol.</i> 2014;13:204-10.	1.678	0.215
95.	A.-C. Piguët, S. Majumder, U. Maheshwari, R. Manunathan, U. Saran, S. Chatterjee, J-F. Dufour . Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities. <i>Clin Sci (Lond).</i> 2014;126:775-84.	4.936	0.898
96.	R. Maan. AJ van der Meer, BE Hansen, JJ Feld, H Wedemeyer, J-F. Dufour , HF Zangneh, F. Lammert, MP Manns, S. ZeuzemHL. , Janssen, RJ de Knegt, BJ. Veldt. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>J Hepatol.</i> 2014;61:482-91.	12.486	0.949
97.	YL. Liu, HL. Reeves, AD. Burt, D. Tiniakos, S. McPherson, JB. Leathart, ME Allison, GJ Alexander, A-C. Piguët, R. Anty, P. Donaldson, GP. Aithal, S. Francque, L. Van Gaal, K. Clement, V. Ratziu, J-F. Dufour , CP Day, AK Daly, QM Anstee. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nat Commun.</i> 2014;5:4309.	12.124	0.968
98.	D. Beyoğlu, KW. Krausz, J. Martin, O. Maurhofer, J. Dorow, U. Ceglarek, FJ. Gonzalez, J-F. Dufour , JR. Idle. Disruption of tumor suppressor gene Hint1 leads to remodeling of the lipid metabolic phenotype of mouse liver. <i>J Lipid Res.</i> 2014;55:2309-19.	4.81	0.814
99.	A. van der Meer, H. Wedemeyer, JJ. Feld, J-F. Dufour , S. Zeuzem, B. Hansen, H. Janssen. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. <i>JAMA.</i> 2014;312:1927-8.	16.538	0.968

100.	AJ. van der Meer, BE Hansen, G. Fattovich, JJ. Feld, H. Wedemeyer, J-F. Dufour , F. Lammert, A. Duarte-Rojo, MP. Manns, D. Ieluzzi, S. Zeuzem, WP. Hofmann, RJ de Knegt, BJ. Veldt, HL. Janssen. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> . 2015;64:322-31.		
101	M. Zochowska, A-C. Piguet, J. Jemielity, J. Kowalska, E. Szolajska, J-F. Dufour , J. Chroboczek. Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> . 2015;11:67-76.		
102.	S. Rueger, P-Y. Bochud, J-F. Dufour , B. Mullhaupt, D. Semela, M. Heim, D. Moradpour, A. Cerny, R. Malinverni, D. Booth, V. Suppiah, J. George, L. Argiro, P. Halfon, M. Bourliere, A. Talal, I. Jacobson, E. Patin, B. Nalpas, T. Poynard, S. Pol, L. Abel, Z. Kutalik, F. Negro. Impact of common risk factors of fibrosis progression in chronic hepatitis C. <i>Gut</i> . 2015;64:1605-15.		
103.	S. Zeuzem, J-F. Dufour , . M. Buti, V. Soriano, R. Buynak, P. Mantry, J. Taunk, J. Stern, R. Vinisko, JP. Gallivan, W. Böcher, FJ. Mensa; the SOUND-C3 study group. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. <i>Liver Int</i> . 2015;35:417-21.		
104.	G. Diserens, M. Vermathen, C. Precht, NT. Broskey, C. Boesch, F. Amati, J-F. Dufour , P. Vermathen. Separation of small metabolites and lipids in spectra from biopsies by diffusion-weighted HR-MAS NMR: a feasibility study. <i>Analyst</i> . 2015;140:272-9.		
105.	P. Ferenci, T. Asselah, GR. Foster, S. Zeuzem, C. Sarrazin, C. Moreno, D. Ouzan, M. Maevskaya, F. Calinas, LE. Morano, J. Crespo, J-F. Dufour , M. Bourlière, K. Agarwal, D. Forton, M. Schuchmann, E. Zehnter, S. Nishiguchi, M. Omata, G. Kukulj, Y. Datsenko, M. Garcia, J. Scherer, AM. Quinson, J.O. Stern; on behalf of the STARTVerso1 study group. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>J Hepatol</i> . 2015;62:1246-55.		
106.	A-C. Piguet, U. Saran, C. Simillion, I. Keller, L. Terracciano, HL. Reeves, J-F. Dufour . Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. <i>J Hepatol</i> 2015;62:1296-303.		
107.	R. Maan, AJ. van der Meer, BE. Hansen , JJ. Feld, H. Wedemeyer, J-F. Dufour , F. Lammert, MP. Manns, S. Zeuzem, HL. Janssen, RJ. de Knegt, BJ. Veldt. Risk of infections during interferon-based treatment in patients with chronic HCV infection and advanced hepatic fibrosis. <i>J Gastroenterol Hepatol</i> . 2015;30:1057-64.		
108.	C. Toso, G. Meeberg, R. Hernandez-Alejandro, J-F. Dufour , P. Marotta, P. Majno, NM. Kneteman. Total Tumor Volume and Alpha Fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. <i>Hepatology</i> . 2015;62:158-65.		

109.	Q. Wang, P. Sachse, M. Semmo, M. Lokhande, M. Montani, J-F. Dufour , F. Zoulim, P. Klenerman, N. Semmo. T- and B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patients. <i>J Viral Hepat.</i> 2015;22:1068-78.		
110.	H. Wang, S. El Maadidi, J. Fischer, E. Grabski, S. Dickhöfer, S. Klimosch, SM. Flannery, A. Filomena, OO. Wolz, N. Schneiderhan-Marra, MW. Löffler, M. Wiese, T. Pichulik, B. Müllhaupt, D. Semela, J-F. Dufour , East-German and Swiss Hepatitis C Virus Study Groups, PY. Bochud, AG. Bowie, U. Kalinke, T. Berg, AN. Weber. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. <i>Hepatology.</i> 2015;62:1375-87.		
111.	Richani M, Kolly P, Knoepfli M, Herrmann E, Zweifel M, von Tengg-Kobligk H, Candinas D, J-F. Dufour . Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. <i>Ann Hepatol.</i> 2015;15(1):82-90.		
112.	C. Hirzel, G. Wandeler, M. Owczarek, M. Gorgievski-Hrisoho, J-F. Dufour , N. Semmo, S. Zürcher. Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study. <i>BMC Infect Dis.</i> 2015;15:483.		
113.	A-C. Piguet, M. Medová, A. Keogh, AA. Glück, DM. Aebersold, J-F. Dufour , Y. Zimmer. Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. <i>Genes Cancer.</i> 2015;6:317-27.		
114.	S. Buhler, E. Giostra, C. Gbame, C. de Rham, B. Müllhaupt, J-F. Dufour , P. Majno, F. Negro, PY. Bochud, J. Villard; Swiss Hepatitis C Cohort Study (SCCS) and Swiss Transplant Cohort Study (STCS). A significant effect of the KIR ligand HLA-C on fibrosis progression in chronic C hepatitis with or without liver transplantation. <i>Liver Int.</i> 2016;36(9):1331-9.		
115.	P. Kolly, H. Reeves, B. Sangro, M. Knöpfli, D. Candinas, J-F. Dufour . Assessment of the Hong Kong Liver Cancer Staging System in Europe. <i>Liver Int.</i> 2016;36:911-7.		
116.	AJ. van der Meer, R. Maan, BJ. Veldt, JJ. Feld, H. Wedemeyer, J-F. Dufour , F. Lammert, A. Duarte-Rojo, MP. Manns, S. Zeuzem, W. Peter Hofmann, RJ. de Knegt, BE. Hansen, HL. Janssen. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>J Gastroenterol Hepatol.</i> 2016;31(6):1168-76.		
117.	L. Quteineh, PY. Bochud, D. Golshayan, S. Crettol, JP. Venetz, O. Manuel, Z. Kutalik, A. Treyer, R. Lehmann, NJ. Mueller, I. Binet, C. van Delden, J. Steiger, P. Mohacsi, J-F. Dufour , PM. Soccal, M. Pascual, CB Eap and The Swiss Transplant Cohort Study. CRT2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. <i>Pharmacogenomics J.</i> 2016; 17(1):69-75.		

118.	GR. Foster, P. Ferenci, T. Asselah, P. Mantry, J-F. Dufour , M. Bourlière, D. Forton, M. Maevskaia, D. Wright, EM. Yoshida, J. García-Samaniego, C. Oliveira, M. Wright, N. Warner, N. Sha, AM. Quinson, JO. Stern. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. <i>J Viral Hepat.</i> 2016;23(3):227-31.		
119.	J. Martin, ML. Balmer, S. Rajendran, O. Maurhofer, J-F. Dufour , MV. St-Pierre. Nutritional stress exacerbates hepatic steatosis induced by deletion of the histidine nucleotide-binding (Hint2) mitochondrial protein. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2016 Apr 1;310(7):G497-509.		
120.	D. Koeberle, J-F. Dufour , G. Demeter, Q. Li, K. Ribí, P. Samaras, P. Saletti, AD. Roth, D. Horber, M. Buehlmann, AD. Wagner, M. Montemurro, G. Lakatos, J. Feilchenfeldt, M. Peck-Radosavljevic, D. Rauch, B. Tschanz, G. Bodoky. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Swiss Group for Clinical Cancer Research (SAKK). <i>Ann Oncol.</i> 2016 May;27(5):856-61.		
121.	M. Manns, D. Samuel, EJ. Gane, D. Mutimer, G. McCaughan, M. Buti, M. Prieto, JL. Calleja, M. Peck-Radosavljevic, B. Müllhaupt, K. Agarwal, P. Angus, EM. Yoshida, M. Colombo, M. Rizzetto, H. Dvory-Sobol, J. Denning, S. Arterburn, PS. Pang, D. Brainard, JG. McHutchison, J-F. Dufour , H. Van Vlierberghe, B. van Hoek, X. Forns. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. SOLAR-2 investigators. <i>Lancet Infect Dis.</i> 2016 Jun;16(6):685-97.		
122.	C. Zahnd, L. Salazar-Vizcaya, J-F. Dufour, B. Müllhaupt, G. Wandeler, R. Kouyos, J. Estill, B. Bertisch, A. Rauch, O. Keiser. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. <i>Swiss HIV; Swiss Hepatitis C Cohort Studies. J Hepatol.</i> 2016 Jul;65(1):26-32.		
123.	R. Maan, R. Zaim, AJ. van der Meer, JJ. Feld, H. Wedemeyer, J-F. Dufour , F. Lammert, MP. Manns, S. Zeuzem, BE. Hansen, HL. Janssen, BJ. Veldt, RJ. de Knegt, CA. de Groot. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>J Gastroenterol Hepatol.</i> 2016;31(11):1851-1859.		
124.	S. Zeuzem, P. Mantry, V. Soriano, RJ. Buynak, J-F. Dufour , PJ. Pockros, D. Wright, P. Angus, M. Buti, JO. Stern, W. Kadus, R. Vinisko, W. Böcher, FJ. Mensa. Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. <i>Eur J Gastroenterol Hepatol.</i> 2016 Aug;28(8):923-6.		

125.	N. Calo, P. Ramadori, C. Sobolewski, Y. Romero, C. Maeder, M. Fournier, P. Rantakari, FP. Zhang, M. Poutanen, J-F. Dufour , B. Humar, S. Nef, M. Foti. Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. <i>Gut</i> . 2016; 65(11):1871-1881.		
126.	A. Teufel, T. Itzel, W. Erhart, M. Brosch, XY. Wang, YO. Kim, W. von Schönfels, A. Herrmann, S. Brückner, F. Stickel, J-F. Dufour , T. Chavakis, C. Hellerbrand, R. Spang, T. Maass, T. Becker, S. Schreiber, C. Schafmayer, D. Schuppan, J. Hampe. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. <i>Gastroenterology</i> . 2016;151(3):513-525.		
127.	M. Munteanu, D. Tiniakos, Q. Anstee, F. Charlotte, G. Marchesini, E. Bugianesi, M. Trauner, M. Romero Gomez, C. Oliveira, C. Day, J-F. Dufour , S. Bellentani, Y. Ngo, S. Traussnig, H. Perazzo, O. Deckmyn, P. Bedossa, V. Ratziu, T. Poynard; FLIP Consortium and the FibroFrance Group. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. <i>Aliment Pharmacol Ther</i> . 2016;44(8):877-89.		
128.	M. Linecker, P. Limani, P. Kambakamba, P. Kron, C. Tschuor, N. Calo, M. Foti, J-F. Dufour , R. Graf, B. Humar, PA. Clavien. Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy. <i>Ann Surg</i> . 2017;324-332.		
129.	L. Quteineh, PY. Bochud, D. Golshayan, S. Crettol, JP. Venetz, O. Manuel, Z. Kutalik, A. Treyer, R. Lehmann, NJ. Mueller, I. Binet, C. van Delden, J. Steiger, P. Mohacsi, J-F. Dufour , PM. Socal, M. Pascual, CB. Eap and The Swiss Transplant Cohort Study. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. <i>Pharmacogenomics J</i> . 2017; 69-75.		
130.	A. Hari, HK. Nair, A. De Gottardi, I. Baumgartner, J-F. Dufour , A. Berzigotti. Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. <i>Liver Int</i> . 2017 Jan;37(1):148-154.		
131.	EB. Tapper, MS. Hughes, M. Buti, J-F. Dufour , S. Flamm, S. Firdoos, MP. Curry, NH. Afdhal. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. <i>Transplantation</i> . 2017 May;101(5):987-995.		
132.	S. McPherson, T. Hardy, J-F. Dufour , S. Petta, M. Romero-Gomez, M. Allison, CP. Oliveira, S. Francque, L. Van Gaal, JM. Schattenberg, D. Tiniakos, A. Burt, E. Bugianesi, V. Ratziu, CP. Day, QM. Anstee. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>Am J Gastroenterol</i> 2017;112:740-751.		
133.	PL. Lévy, S. Duponchel, H. Eischeid, J. Molle, M. Michelet, G. Diserens, M. Vermathen, P. Vermathen, J-F. Dufour , HP. Dienes, HM. Steffen, M. Odenthal, F. Zoulim, B. Bartosch. Hepatitis C virus infection triggers a tumor-like glutamine metabolism. <i>Hepatology</i> . 2017 Mar;65(3):789-803.		

134.	E. Herrmann, D. Naehrig, M. Sassowsky, M. Bigler, J. Buijsen, I. Ciernik, D. Zwahlen, AF. Pellanda, A. Meister, P. Brauchli, S. Berardi, E. Kuettel, J-F. Dufour , DM. Aebbersold, Swiss Group for Clinical Cancer Research (SAKK). External beam radiotherapy for unresectable hepatocellular carcinoma, an international multi-center phase I trial, SAKK 77/07 and SASL 26. <i>Radiat Oncol.</i> 2017.		
135.	E. Kachaylo, C. Tschuor, N. Calo, N. Borgeaud, P. Limani, A-C. Piguet, J-F. Dufour , M. Foti, R. Graf, PA. Clavien, B. Humar. PTEN downregulation promotes β -oxidation to fuel hypertrophic liver growth after hepatectomy in mice. <i>Hepatology.</i> 2017 Sep;66(3):908-921.		
138.	P. Kolly, M. Knöpfli, J-F. Dufour . Effect of Smoking on Survival of Patients with Hepatocellular Carcinoma. <i>Liver Int.</i> May 2017 May; 3(10.1111)/liv.13466.		
139.	P. Kolly, O. Waidmann, J. Vermehren, C. Moreno, I. Vögeli, T. Berg, D. Semela, S. Zeuzem, J-F. Dufour . Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. <i>J Hepatol.</i> 2017;67:876-878.		
140.	O. Keiser, F. Giudici, B. Müllhaupt, C. Junker, J-F. Dufour , D. Moradpour, P. Bruggmann, B. Terziroli, D. Semela, M. Brezzi, B. Bertisch, J. Estill, F. Negro, A. Spoerri; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. <i>J Viral Hepat.</i> 2018;25:152-160.		
141.	N. Saigi-Morgui, L. Quteineh, PY. Bochud, S. Crettol, Z. Kutalik, NJ. Mueller, I. Binet, C. Van Delden, J. Steiger, P.Mohacsi, J-F. Dufour , PM. Socal, M. Pascual, CB. Eap; Swiss Transplant Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. <i>Pharmacogenomics J.</i> 2017 In Press.		
142.	A. Gmür, P. Kolly, M. Knöpfli, J-F. Dufour . FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status. <i>Liver Int.</i> 2018 In Press		
143.	M. Puoti, GR. Foster, S. Wang, D. Mutimer, E. Gane, C. Moreno, TT. Chang, SS. Lee, R. Marinho, J-F. DuFour , S. Pol, C. Hezode, SG. Gordon, SI Strasser, PJ. Thuluvath, Z. Zhang, S. Lovell, T. Pilot-Matias, FJ. Mensa. High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis. <i>J Hepatol.</i> 2018 In Press.		
144.	R. Rajasekaran, A.Felser, J-M. Nuoffer, J-F. Dufour , MV. St-Pierre. The histidine triad nucleotide-binding protein 2 (HINT-2) positively regulates hepatocellular energy metabolism. <i>FASEB Journal</i> 2018. In Press.		

B. Editorials, Reviews; Guidelines:

IF** *Ranking**

1.	J-F. Dufour , MM. Kaplan. Muddying the water: Wilson's challenges will not soon disappear. <i>Gastroenterology</i> . 1997;113:348-50.	10.250	
2.	J-F. Dufour , C. Redaelli. Survival pathways and preconditioning in liver transplantation. <i>Transplant Immunology</i> . 2002;9:239-241.	1.349	
3.	J-F. Dufour , MV. St-Pierre. Phytotherapeutika in Gastroenterologie und Hepatologie. <i>Therapeutische Umschau</i> . 2002;59:313-316.		
4.	P. Allemann, B. Burckhardt, J-F. Dufour . Transplantation for alcoholic liver disease : the wrong arguments. <i>Swiss Medical Weekly</i> . 2002;132:296-7.	0.770	
5.	C. Oneta, J-F. Dufour . Treatment options in non-alcoholic steatohepatitis according to pathogenic considerations. <i>Swiss Medical Weekly</i> . 2002; 132:493-505.	0.770	
6.	J-F. Dufour . Hepatocellular antifreeze carrier. <i>J Hepatol</i> 2003;39:460-2.	5.283	0.915
7.	E. Schmied, J-F. Dufour , S. Euvrard. Nontumoral dermatologic problems after liver transplantation. <i>Liver Transpl</i> 2004;10:331-9.	3.984	0.964
8.	D. Semela, J-F. Dufour . Angiogenesis and hepatocellular carcinoma. <i>J Hepatol</i> 2004;41:864-80.	4.816	0.935
9.	J-F. Dufour , M. Fey. What is the current treatment of post-transplant lymphoproliferative disorders after liver transplantation? <i>J Hepatol</i> 2006;44:23-6.	6.073	0.936
10.	A. De Gottardi, J-F. Dufour . Die Ösophagus-/Fundus-Varizen-Blutung. <i>Therapeutische Umschau</i> . 2006;63:295-300.	6.642	0.94
11.	J-F. Dufour . Met-hodology. <i>J Hepatology</i> 2007;46:748-8.	6.642	0.94
12.	J-F. Dufour . NASH and thiazolidinediones: not to be taken lightly. <i>J Hepatology</i> 2007;47:451-3.	6.642	0.94
13.	J-F. Dufour , O. Huber, S. Kozma, R. Toftgard. Tumour suppressors in liver carcinogenesis. <i>J Hepatol</i> . 2007;47:860-7.	6.642	0.94
14.	J. Martin, J-F. Dufour . Tumor suppressors and hepatocellular carcinoma. <i>World J Gastroenterology</i> . 2008;14:1720-33.	2.081	0.436
15.	P. Romanque, A-C. Piguët, J-F. Dufour . Targeting vessels to treat hepatocellular carcinoma. <i>Clin Sci</i> 2008;114:467-77.	4.187	0.852
16.	M. Balmer, J-F. Dufour . Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. <i>Swiss Med Wkly</i> . 2008;138:415-9.	1.436	0.495
17.	B. Strebél, J-F. Dufour . Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. <i>Expert Rev Anticancer Ther</i> . 2008;8:1743-9.	2.296	0.381
18.	J-F. Dufour . The evasive promise of antiangiogenic therapy. <i>J Hepatol</i> . 2009;51:970-2.	7.818	0.953
19.	J-F. Dufour . Treat the bones and get less rejection. <i>Liver International</i> . 2010;30:337-8.	3.84	0.786
20.	J-F. Dufour , P. Johnson. Liver Cancer: From Molecular Pathogenesis to new therapies. Summary of a Single Topic Conference. <i>J. Hepatol</i> . 2010;52:296-304.	9.334	0.957

21.	J-F. Dufour. Vitamin E for non-alcoholic steatohepatitis: ready for prime time? <i>Hepatology</i> . 2010;52:789-92.	10.885	0.986
22.	J. Martin, J-F. Dufour. Abnormal nitrosothiol metabolism in hepatocellular carcinoma. 2011;54:579-80.	9.264	0.959
23.	M. Haedrich, J-F. Dufour. UDCA for NASH: end of the story? <i>J. Hepatol.</i> 2011;54:856-8.	9.264	0.959
24.	A-C. Piguet, J-F. Dufour. PI(3)K/PTEN/AKT Pathway. <i>J Hepatol.</i> 2011;54:1317-9.	9.264	0.959
25.	J. Martin, MV. St-Pierre, J-F. Dufour. HIT proteins, mitochondria and cancer. <i>Biochim Biophys Acta.</i> 2011;1807:626-632.	3.022	0.559
26.	ML. Balmer, J-F. Dufour. Non-alcoholic steatohepatitis – from NAFLD to MAFLD. <i>Ther Umsch.</i> 2011;68:183-8.	-	-
27.	FY. Yao, S. Breitenstein, CE. Broeschl, J-F. Dufour, M. Sherman. Does a patient qualify for liver transplantation after down-staging of hepatocellular carcinoma. <i>Liver Transplantation</i> 2011;17:S109-116.	3.386	0.929
28.	MV. St-Pierre, J-F: Dufour. Biomarkers for hepatocellular apoptosis in the management of liver diseases. <i>Curr. Pharm. Biotechnol.</i> 2012; 2221-2227.	-	-
29.	B. Morell, J-F. Dufour. Liver transplantation - when and for whom it should be performed. <i>Ther Umsch.</i> 2011;68:707-13.	2.69	0.63
30.	Swiss Association for the Study of the Liver. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. <i>Swiss Med Wkly.</i> 2012;24;142:w13516.	1.821	0.682
31.	J-F. Dufour. TACE with or without systemic therapy? <i>J Hepatol.</i> 2012;56:1224-5.	9.858	0.945
32.	J-F. Dufour. Anti-angiogenic therapy for HCC. <i>Minerva Gastroenterol Dietol.</i> 2012;58:81-6.	-	-
33.	European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. <i>J Hepatol.</i> 2012;56:908-43.	9.858	0.945
34.	F. Liechti, J-F. Dufour. Treatment of NASH with ursodeoxycholic acid: <i>Cons. Clin Res Hepatol Gastroenterol.</i> 2012;36 Suppl 1:S46-52.	1.348	0.178
35.	L. Bolondi, A. Burroughs, J-F. Dufour, PR. Galle, V. Mazzaferro, F. Piscaglia, JL. Raoul, B. Sangro. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Semin Liver Dis.</i> 2012;32:348-59.	8.274	0.932
36.	A-C. Bürgi, J-F. Dufour. Treatment of non-alcoholic steatohepatitis. <i>Rev Prat.</i> 2012;62:1425-7.	-	-
37.	J-F. Dufour, C-reactive protein, a prognostic marker in HCC. <i>Hepatology.</i> 2013;57:2103-5.	11.19	0.973
38.	J-F. Dufour, Modern hepatomancy. <i>Gastroenterology.</i> 2013;144:876-8.	13.926	1
39.	J-F. Dufour, I. Bargellini, N. De Maria, P. De Simone, I. Goulis, RT. Marinho. Intermediate hepatocellular carcinoma : current treatments and future perspectives. <i>Ann Oncol.</i> 2013;Suppl 2:ii24-9.	6.578	0.915

40.	AB. Leichtle, J-F. Dufour , GM. Fiedler. Potentials and pitfalls of clinical peptidomics and metabolomics. Swiss Med Wkly. 2013;143:w13801.	1.877	0.678
41.	S. Tonko, J-F. Dufour , (Hepatology scores). Ther Umsch. 2013;70:577-9.	-	-
42.	J-F. Dufour . Hepatology highlights. Hepatology. 2013;58:1869-70.	11.19	0.973
43.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;59:1-3.	13.246	0.962
44.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;59:357-9.	13.246	0.962
45.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;59:743-5.	13.246	0.962
46.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;59:1217-9.	13.246	0.962
47.	H. Perazzo, T. Poynard, J-F. Dufour . The interactions of nonalcoholic fatty liver disease and cardiovascular disease. Clin Liver Dis. 2014;18:233-48.	13.246	0.962
48.	J-F. Dufour . Hepatocellular carcinoma. Sorafenib--for once age is not an issue. Nat Rev Gastroenterol Hepatol. 2014;11:273-4.	13.246	0.962
49.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;59:1721-2.	13.246	0.962
50.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;59:2059-61.	13.246	0.962
51.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;60:1-3.	13.246	0.962
52.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;60:445-7.	13.246	0.962
53.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;60:773-5.	13.246	0.962
54.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;60:1119-20.	13.246	0.962
55.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;60:1455-7.	13.246	0.962
56.	J-F. Dufour . Hepatology highlights. Hepatology. 2014;60:1803-5.	13.246	0.962
57.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;61:1-3.		
58.	G. Wandeler, J-F. Dufour , P. Bruggmann, A. Rauch. Hepatitis C: a changing epidemic. Swiss Med Wkly. 2015;145:w14093.		
59.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;61:411-2.		
60.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;61:741-3.		
61.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;61:1101-3.		
62.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;61:1449-51.		
63.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;61:1773-5.		
64.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;62:1-3.		
65.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;62:327-9.		
66.	J-F. Dufour . Hepatology highlights. Hepatology. 2015;62:663-5.		
67.	U. Saran, B. Humar, P. Kolly, J-F. Dufour . Hepatocellular carcinoma and lifestyles. J Hepatol. 2015.		
68.	U. Saran, M. Foti, J-F. Dufour . Cellular and molecular effects of the mTOR inhibitor everolimus. Clin Sci. 2015.		
69.	A. Berzigotti, U. Saran, J-F. Dufour . Physical activity and liver diseases. Hepatology.2015.		
70.	C. Pocha, P. Kolly, J-F. Dufour . Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude. Semin Liver Dis. 2015;35:304-17.		
71.	J-F. Dufour . Time to Abandon NASH? Hepatology. 2016;63:9-10.		
72.	C. Margini, J-F. Dufour . The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 2016; 36(3):317-24.		

73.	I. Bartella, J-F. Dufour . Clinical Diagnosis and Staging of Intrahepatic Cholangiocarcinoma. <i>J Gastrointest Liver Dis.</i> 2015;24:481-9.		
74.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2015;62:985-7.		
75.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2015;62:1331-3.		
76.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2015;62:1649-51.		
77.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;63:9-10.		
78.	Surveillance for Hepatocellular Carcinoma in Patients with NASH. P. Kolly, J-F. Dufour . <i>Diagnostics (Basel).</i> 2016; 6(2). pii: E22.		
79.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;63:679-81.		
80.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;63:1026-40.		
81.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;63:1065-67.		
82.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;63:1405-7.		
83.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;63:1749-51.		
84.	A. Teufel, J-F. Dufour . Two-Step Forward Genetic Screen in Mice Identifies the Ral Pathway as a Central Drug Target in Hepatocellular Carcinoma. <i>Gastroenterology.</i> 2016; 151(2):231-3.		
85.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;64:1-3.		
86.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;64:325-7.		
87.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;64:703-5.		
88.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;64:1011-3.		
89.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;64:1395-7.		
90.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2016;64:1829-30.		
91.	H. Perazzo, J-F. Dufour . The therapeutic landscape of non-alcoholic steatohepatitis. <i>Liver Int</i> 2017;37(5):634-647.		
92.	A. Scherer, J-F. Dufour . Treatment of Non-Alcoholic Fatty Liver Disease. <i>Dig Dis.</i> 2016;34 Suppl 1:27-31.		
93.	L. von Köckritz, J-F. Dufour . Management of chronic hepatitis C in 2017. <i>Hamostaseologie</i> 2017; 37(3):186-195.		
94.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2017;65:1-3.		
95.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2017;65:399-400		
96.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2017;65:761-762		
97.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2017;65:1081-1083		
98.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2017;65:1429-1431		
99.	J-F. Dufour . Hepatology highlights. <i>Hepatology.</i> 2017;65:1783-1784.		
100.	P. Kolly, J-F. Dufour . Patients with hepatocellular carcinoma: Your address matters! <i>J Hepatol.</i> 2017 Mar;66(3):480-481.		
101.	H. Perazzo, J-F. Dufour . The therapeutic landscape of non-alcoholic steatohepatitis. <i>Liver Int.</i> 2017 May;37(5):634-647.		
102.	P. Kolly, O. Waidmann, J. Vermehren, C. Moreno, I. Vögeli, T. Berg, D. Semela, S. Zeuzem, J-F. Dufour . Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. <i>J Hepatol.</i> 2017 Jul; S0168-8278.		
103.	D. Segna, J-F. Dufour . Other Extrahepatic Manifestations of Hepatitis C Virus Infection (Pulmonary, Idiopathic Thrombocytopenic Purpura, Nondiabetes Endocrine Disorders). <i>Clin Liver Dis.</i> 2017 Aug;21(3):607-629.		
104.	C. Rauh, J-F. Dufour . Nichtalkoholische Fettlebererkrankung (NAFLD). <i>Therapeutische Umschau</i> 2017 Jul;74(3):87-92.		

105.	A. Gerbes, F. Zoulim, H. Tilg, J-F. Dufour , J. Bruix, V. Paradis, R. Salem, M. Peck-Radosavljevic, PR. Galle, TF. Greten, JC. Nault, MA. Avila. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388.		
------	---	--	--

C. Letters to the Editor, Case reports:

		*IF	**Ranking
1.	P. Beris, J-F. Dufour . Treatment of autoimmune thrombocytopenic purpura. Letter. N. Engl. J. Med. 1989;321:760-761.		
2.	C. Seiler, J-F. Dufour . Survival after liver transplantation. Lancet. 2001;357:72.	13.251	
3.	F. Mosimann, J-J. Gonvers, G. Mentha, E. Giostra, C. Seiler, J-F. Dufour , P. Morel. Liver allocation in Switzerland. Liver Transplantation. 2002;8:88.	3.786	
4.	P. Romanque, F. Stickel, J-F. Dufour . Disproportionally high transient elastography Values in patients with autoimmune hepatitis. Liver International 2008;8:1177-8.	2.908	0.655
5.	M. Röther, J-F. Dufour , B. Schnüriger. An uncommon cause of a focal liver lesion. Gastroenterology. 2013;144:510-659.	13.926	1
6.	R. Thattil, J-F. Dufour . Hepatocellular carcinoma in a non-cirrhotic patient with Wilson's disease. World J Gastroenterol. 2013;19:2110-3.	2.433	0.527
7.	U. Bechtel-Grosch, C. Beguelin, S. Berezowska, J-F. Dufour , Takala J, Schefold JC. Fulminant hepatic and multiple organ failure following acute viral tonsillitis: a case report. J Med Case Rep. 2016;10:7.		
8.	P. Kolly, J-F. Dufour . A strong message is needed to address the issue of HCC recurrence after DAA therapy. J Hepatol. 2016 Dec;65(6):1268-1269.		
9.	R. Bill, M. Montani, B. Blum, J-F. Dufour , R. Escher, M. Bühlmann. Favorable response to mTOR inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. Hepatology. 2018 In Press.		

* **Impact factor**

** **Maximum-Ranking according to Journal Index**

(www.medizin.unibe.ch/forschung/journalindex/index_ger.html)

D. Book's chapters, electronic media:

1. J. Cotting, **J-F. Dufour**, P. Lentze, J. Reichen. Ursodeoxycholate in the treatment of cholestasis in cystic fibrosis. In 'Paediatric Cholestasis.' Falk Symposium 63;345-353. Kluwer academic publishers, 1992.
2. **J-F. Dufour**, M. Kaplan. The antifibrotic effect of interferon in the treatment of hepatitis C: an unanticipated but important endpoint. *Medscape Gastroenterology (eMed Journal)*. May/June 2000 Vol 2 Number 3.
3. **J-F. Dufour**, E. Schmied. Dermatologic problems in patients, who have undergone liver transplantation. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2000.
4. **J-F. Dufour**. Non-alcoholic steatohepatitis. Review. OrphaNet. March 2001.
5. **J-F. Dufour**. Tocopherol and antioxidants in the treatment of the non-alcoholic steatohepatitis. In 'Non-alcoholic and Alcoholic steatohepatitis.' Falk Symposium 121;197-202. Kluwer academic publishers, 2001.
6. D. Semela, **J-F. Dufour**. Vascular endothelial growth factor signaling. In: **J-F. Dufour**, P-A Clavien eds. Signaling pathways in Liver diseases. Springer 2005.
7. E. Renner, **J-F. Dufour**. Medical problems after liver transplantation. In: P. Killenberg, P-A. Clavien eds. Medical care of the liver transplant patient. Third Ed. Blackwell 2006.
8. **J-F. Dufour**. Biliary epithelial cells. In: J-P. Benhamou, A. Blei, **J-F Dufour**, P. Ginès, S. Friedmann, J. Reichen, J. Rodes, C. Valla, F. Zoulim eds. Oxford Textbook of Hepatology. Third Ed. Blackwell 2007.
9. D. Semela, **J-F. Dufour**. Vascular endothelial growth factor signaling. In: **J-F. Dufour**, P-A Clavien eds. Signaling pathways in Liver diseases. Second Edition. Springer 2009.
10. ML. Balmer, **J-F. Dufour**. Molecular mechanisms of liver cancer metastasis. In: L. Qiao, J. George, eds. Liver Cancer E-book. Bantham Publishers. 2012.
11. C. Hora, **J-F. Dufour**. Primary Hepatocellular Carcinoma. In: P. Monga, ed. Molecular Pathology of Liver Diseases. Springer. 2011.
12. ML. Balmer, **J-F. Dufour**. Biology of Hepatocellular Carcinoma. In: McMasters KM, Vauthey JN, eds. Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care. Springer. 2010.
13. A. Sendensky, **J-F. Dufour**. Physiology of Liver Functions. In: P.Gines, P. Kamath, V. Arroyo. Chronic Liver Failure: Mechanisms and Management. Springer. 2010.
14. A. Buergi, **J-F. Dufour**. Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines. In: Eds. Geoff Farrell (Canberra, Australia), Arthur McCullough (Cleveland, USA), Christopher Day (Newcastle, UK). Non-alcoholic fatty liver disease. A practical guide. 2013.

15. C. Margini, **J-F. Dufour**. Are the guidelines—AASLD, IASL, EASL, and BSG—of help in the management of patients with NAFLD? In R. Williams and S. D. Taylor-Robinson. Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease. John Wiley & Sons. 2016.

E. Book editor:

1. Signaling Pathways in Liver Diseases. Springer 2005. **J-F. Dufour**, P-A. Clavien, Editors. (35 chapters).

2. Oxford Textbook of Hepatology. Third Ed. Blackwell. JP Benhamou, A. Blei, **J-F Dufour**, P. Ginès, S. Friedmann, J. Reichen, J. Rodes, C. Valla, F. Zoulim Editors. Blackwell 2007.

3. Signaling Pathways in Liver Diseases. Second Edition. Springer 2009. **J-F. Dufour**, P-A. Clavien, Editors. (35 chapters).

4. Signaling Pathways in Liver Diseases. Third Edition. Wiley 2015. **J-F. Dufour**, P-A. Clavien, Editors. (35 chapters).